cms.bioaccessla.com

Tag: Brazil

  • Brazil’s 90 Day Clinical Trial Review Cap: What Medtech Sponsors Should Do Before Submitting

    Brazil’s 90-Day Clinical Trial Review Cap: What MedTech Sponsors Should Do Before Submitting

    Brazil has moved from being a “high-potential but unpredictable” country for early-stage MedTech studies to a jurisdiction with a defined statutory review clock. For sponsors, that shift is not just a speed story — it is a planning story. When review timelines become shorter and more predictable, the relative impact of preventable sponsor-side errors gets larger.

    This article is written for MedTech founders, clinical operations leaders, and regulatory directors who want to run first-in-human (FIH) or early feasibility work in Brazil without losing weeks to rework. We focus on what you can control before submission: dossier readiness, ethics strategy, local operational prerequisites, and vendor orchestration.

    Why a faster regulatory clock changes the sponsor playbook

    Short timelines compress decision-making. If you used to “fix it after ANVISA feedback,” you may no longer have that luxury — because site contracts, import permits, radiology workflows, and ethics committee coordination can become the rate-limiting steps. A faster clock also forces clearer internal governance: who owns the final protocol, the risk assessment, the device technical file, and the country-specific annexes?

    Practically, the sponsor question becomes: How do we arrive at Day 0 with no missing pieces? The goal is to avoid pauses caused by translation gaps, document format mismatches, incomplete investigator packages, or unaligned device documentation.

    Pre-submission checklist: what to lock down before Day 0

    • Protocol version control: Confirm the final protocol, synopsis, schedule of assessments, and statistical plan are aligned — and that the same versions appear in every submission component.
    • Risk classification and device description: Ensure the device description, intended use, instructions for use, and risk analysis are consistent across documents. Inconsistency is one of the most common sources of questions.
    • Investigator and site packages: Collect CVs, training evidence, GCP documentation, and site capabilities early. In Brazil, the operational readiness of sites can become as important as the regulatory dossier.
    • Translations and local formatting: Build time for Portuguese localization and formatting checks. A strong translation is not only linguistic — it must preserve clinical meaning and match annex references.
    • Informed consent strategy: Prepare consent language that is clear, compliant, and aligned to local norms. If your device includes software, connectivity, or data transfer, incorporate that into consent and data handling text.
    • Import and logistics planning: Map the path for device shipment, labeling, and storage. Even for non-radioactive devices, customs, temperature needs, and distribution responsibilities can derail timelines.

    Parallel ethics + regulatory review: how to operationalize it

    When a system allows parallel tracks, the bottleneck often shifts to coordination. Sponsors should treat ethics submission as a project with its own critical path, not as an administrative afterthought. Build a unified submission calendar and align on:

    • Sequence of internal approvals: Decide who signs off on ethics content and who owns final responses.
    • Site-by-site variance: Even with a national framework, each site can introduce operational nuance. Standardize as much as possible, but plan for local adjustments.
    • Response management: Pre-write response templates for common questions (risk/benefit, recruitment strategy, device safety, data management) so you can move quickly.

    For FIH and early-stage work, ethics committees will often focus on patient protection and feasibility: training, emergency procedures, follow-up, and the practical ability of the site to manage adverse events. Your dossier should show readiness, not just compliance.

    What MedTech sponsors often underestimate in Brazil

    Speed-friendly frameworks do not eliminate complexity; they amplify the cost of under-planning. The most common underestimates include:

    • Data and privacy workflows: If your study uses digital endpoints or remote monitoring, align data flows, storage, and access controls early.
    • Device accountability: Plan how devices will be tracked, stored, returned, and reconciled. Accountability gaps create audit risk and can slow activation.
    • Training: Documented training is not optional in early-stage device studies. Build training into your timeline and capture evidence systematically.
    • Vendor interdependencies: CRO, imaging core lab, shipping/logistics, and local regulatory support must operate from the same timeline assumptions and document set.

    FAQ

    1) Does a statutory review cap guarantee approval in 90 days?
    No. A cap can improve predictability, but the practical timeline still depends on dossier quality, completeness, and how quickly questions are resolved.

    2) Should we treat Brazil as a first-choice country for FIH studies?
    Brazil can be compelling when the patient population, investigator expertise, and activation path fit the product. Sponsors should evaluate Brazil alongside other Latin American jurisdictions based on feasibility, ethics speed, and operational readiness.

    3) What’s the biggest sponsor-side mistake?
    Submitting with misaligned documents (protocol vs. device description vs. risk file) and assuming issues can be fixed “during review.” In faster systems, that approach often costs more time, not less.

    Bottom line: If your goal is to capture the benefit of a faster review framework, your work starts well before Day 0. A sponsor-side checklist — executed early — is often the difference between a fast approval and a slow cycle of preventable questions.

  • Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil continues to be one of the most important anchors for early-stage clinical development in Latin America, but the compliance baseline is moving. In 2026, Anvisa highlighted that Brazil’s clinical research environment has been updated through Law No. 14.874/2024 (ethical aspects of research with human beings) and the newer regulatory package RDC 945/2024 plus IN 338/2024 for clinical research supporting registration of medicines, which Anvisa notes took effect in early 2025 (Anvisa).

    For MedTech founders and regulatory directors planning first-in-human (FIH) or early pivotal work in the region, the strategic opportunity remains: access to experienced investigators, high-quality sites, and diverse patient populations. The operational requirement, however, is to design submissions, vendor oversight, and essential documentation so you can demonstrate control at any moment—especially as inspection programs mature.

    1) What changed in Brazil’s research governance—and why it matters for sponsors

    Anvisa’s 2025 activity reporting explicitly connects the new ethical law and the updated clinical research regulation to the agency’s current oversight approach (Anvisa). In parallel, Anvisa’s inspection metrics reporting emphasizes inspection readiness against GCP expectations (ICH E6 (R2) or updates) while referencing RDC 945/2024 and Law 14.874/2024 as part of the inspection framework (Anvisa).

    Practical takeaway: even when timelines are competitive, sponsors should assume that documentation quality, vendor governance, and data integrity controls will be evaluated more explicitly. This is good news for well-prepared early-stage teams: strong fundamentals can shorten back-and-forth with sites and reduce downstream remediation.

    2) A sponsor-ready timeline: how to think about “FIH speed” without compliance debt

    Internal execution experience across Latin American programs repeatedly shows that speed usually breaks down in predictable places: incomplete essential documents, misaligned responsibilities between sponsor and CRO, and late-stage changes to protocol and informed consent artifacts. Treat “speed” as a systems outcome rather than a hero effort.

    • Pre-submission (4–8 weeks): lock protocol operational feasibility, confirm investigational product/device logistics, and establish a document control plan.
    • Submission-ready package: create a single source of truth for protocol, IB/IFU (as applicable), safety reporting plan, and data handling plan.
    • Site activation: standardize training, delegation, and vendor onboarding so the first site is not a one-off build.

    Many startups underestimate that “time to first patient” is often constrained by operational readiness, not just authority review. Investing early in a repeatable activation model is one of the highest ROI moves you can make.

    3) Inspection readiness: build once, benefit for years

    Anvisa’s inspection metrics report notes its focus on inspections conducted in 2024 and 2025 and positions inspections as a tool to protect participants and data integrity (Anvisa). For early-stage sponsors, the implication is clear: build inspection readiness into your operating rhythm rather than treating it as a “phase 3 problem.”

    Start with five non-negotiables:

    • Essential document discipline: version control, signatures, and clear ownership.
    • Delegation and training: role-based training mapped to tasks; keep it auditable.
    • Deviation and CAPA workflow: define severity levels and timelines; trend issues.
    • Vendor oversight: documented qualification, KPIs, and periodic review for CROs, labs, and logistics partners.
    • Data integrity: audit trails, access controls, and reconciliation between source, eCRF, and safety database.

    4) How to operationalize this across Latin America (not just Brazil)

    Brazil is rarely the only country in a Latin America strategy. Use Brazil as the quality anchor and replicate the same operating system across additional countries. You can localize what must be localized (ethics committee formats, language, import processes), while keeping your core compliance artifacts stable.

    A useful mental model: create a regional master file (core documents, SOPs, training), plus country modules (local submissions, contracts, import permits), plus site modules (delegation, logs, training, monitoring).

    FAQ

    When did Brazil’s latest clinical research regulations take effect?
    Brazil’s updated framework referenced by Anvisa includes Law 14.874/2024 (in force since 29 Aug 2024) and RDC 945/2024 plus IN 338/2024 (effective 2 Jan 2025).

    Do these changes apply to medical devices too?
    The Anvisa updates cited relate to clinical research for registration of medicines and biologics; device sponsors should still align operational quality systems and inspection readiness to ICH GCP expectations and local ethics requirements.

    How should startups prepare for inspection readiness?
    Build inspection-ready documentation from day one: role-based training, version-controlled essential documents, delegation logs, deviation management, and vendor oversight that can be demonstrated quickly.

    Need help designing a Latin America FIH plan? bioaccess® supports sponsors with regional feasibility, activation, and execution strategies built for speed and inspection readiness.

  • First-In-Human In Brazil In 2026: A Practical Timeline For Sponsors

    First-in-Human in Brazil in 2026: A Practical Timeline for Sponsors

    Primary keyword: first-in-human trial Brazil timeline

    Brazil is increasingly on the shortlist for early-stage clinical development because sponsors can combine a large patient base with growing regulatory clarity. A recent policy analysis argued that Lei 14.874 de 2024 created the basis for a more predictable environment and, for the first time, establishes timelines and greater regulatory clarity for clinical studies.

    This article gives a practical, sponsor-side timeline for launching a first-in-human (FIH) study in Brazil in 2026—what to do first, what typically slows teams down, and how to sequence work so you do not lose weeks to preventable back-and-forth.

    1) Define the “Brazil-ready” FIH package (Weeks 0–2)

    Before any submission, align internal stakeholders on what “Brazil-ready” means. For most MedTech and biopharma sponsors, FIH readiness is not only a protocol question—it is also a documentation and site execution question.

    • Protocol and IB alignment: Ensure endpoints, safety monitoring, and dose-escalation logic are consistent with your global plan.
    • Country adaptations: Identify what must be localized or supplemented (consent language, site materials, labeling, and investigator documentation).
    • Feasibility assumptions: Confirm whether required imaging, lab, or procedural capabilities exist at target sites.

    Internal best practice: Create a single “FIH Brazil master checklist” with owners and due dates. Treat it as a deliverable, not an afterthought.

    2) Select sites for speed, not just prestige (Weeks 1–4)

    In FIH, startup speed is highly correlated with site readiness. Sponsors often choose sites based on reputation, then discover contracting and operational realities late.

    • Prioritize operational maturity: Look for sites with dedicated research staff, established ethics processes, and experience with sponsor audits.
    • Validate recruitment pathways: Treatment-naive populations can be an advantage, but referral networks still matter.
    • Assess import and handling constraints: If your study uses temperature-sensitive materials, confirm storage and chain-of-custody procedures early.

    3) Build a parallel workstream plan (Weeks 2–6)

    The most common timeline mistake is running tasks sequentially that can be executed in parallel. Even when formal review clocks improve, sequential execution can erase the benefit.

    To compress time, run these workstreams at the same time:

    • Regulatory dossier preparation (quality, safety documentation, and trial authorization package)
    • Ethics submission package (site-specific documents and consent)
    • Contracts and budgets (CTA, indemnities, payment schedules, and monitoring model)
    • Supply and logistics readiness (import planning, labeling, storage validation, and back-up scenarios)

    Even when legal reforms aim to improve predictability, sponsors still need coordinated execution across stakeholders to realize those gains.

    4) Anticipate “hidden” startup time: contracts, import, and training (Weeks 4–10)

    Even when review timelines are favorable, sponsors can lose time after approvals due to operational bottlenecks:

    • Contract negotiation cycles: Build buffer time for legal review, redlines, and institutional sign-off.
    • Import and release: If your investigational product or device must be imported, confirm lead times and documentation requirements early.
    • Site initiation and training: FIH trials require strict adherence to safety procedures; schedule training sessions while approvals are in progress.

    Practical tip: Maintain a “go-live readiness dashboard” that tracks contract status, shipment readiness, and training completion. This prevents surprises when the green light arrives.

    5) A sponsor-friendly 2026 FIH timeline (example)

    Every program is different, but a realistic planning template looks like this:

    • Weeks 0–2: Brazil-ready protocol package, checklist, and internal alignment
    • Weeks 1–4: Site selection, feasibility, and early budget/CTA drafts
    • Weeks 2–6: Parallel dossier + ethics package finalization
    • Weeks 4–10: Contracts, import planning, training, and vendor setup
    • Weeks 10–14: Final site activation steps and first-patient readiness

    If you are aiming for speed, measure time-to-ready as rigorously as you measure time-to-approval. In many FIH programs, the fastest sponsors are simply the ones that avoid rework.

    FAQ: First-in-human trial Brazil timeline

    • How long does it take to start a first-in-human trial in Brazil?
      Timelines vary by protocol complexity and site readiness, but sponsors should plan for parallel regulatory and ethics pathways, early document localization, and realistic contracting and import lead times.
    • What is the biggest cause of FIH delays in Brazil?
      In practice, delays often come from incomplete documentation, late site selection, and underestimated startup logistics (contracts, import permits, and investigational product readiness), not just the formal review clock.
    • Can Brazil FIH data support US or EU submissions?
      Yes, when the trial is designed to international GCP standards and endpoints align with your global regulatory strategy, Brazilian data can be part of a broader evidence package.

    Need help planning an FIH startup in Brazil or across Latin America? bioaccess® supports sponsors with country startup planning, site activation, and operational execution—without exposing confidential details publicly.

  • Anvisa’s 2026–2027 International Convergence Agenda: What Medtech Sponsors Need To Plan For

    ANVISA’s 2026–2027 International Convergence Agenda: What MedTech Sponsors Need to Plan For

    Brazil’s medical device regulator, ANVISA, is in the middle of the most aggressive period of international regulatory convergence in its history. Between the mid-2024 Brazilian Clinical Research Law (Lei 14.874) becoming fully operative on January 1, 2025, and the agency’s published 2026–2027 priorities, the rules around clinical trial submissions, post-market surveillance, software as a medical device (SaMD), and unique device identification (UDI) are all changing simultaneously.

    For MedTech sponsors planning to use Brazilian clinical data in US, EU, or Brazilian regulatory submissions, the next 18 months are a strategic window. Here is what is changing, why it matters, and how to plan for it.

    What Is Actually Changing

    Three convergence streams are running in parallel.

    1. Stronger international cooperation on device review. ANVISA has expanded its participation in international regulatory work-sharing arrangements, including the Medical Device Single Audit Program (MDSAP) and increased reliance agreements with FDA, EMA, and Health Canada-equivalent regulators. The practical effect: a device that has cleared review in a recognized reference jurisdiction can move through Brazilian registration substantially faster than under the old country-by-country framework.

    2. New SIUD database and UDI implementation. ANVISA’s Sistema de Informação de Identificação Única de Dispositivos Médicos (SIUD) is being phased in across 2026, requiring UDI assignment, labeling, and database submission for medical devices entering the Brazilian market. The phase-in follows risk class — Class IV (highest risk) and IVDs first, then descending through Class III, II, and I over the multi-year timeline.

    3. Software-as-a-medical-device pathway clarification. ANVISA has published updated normative instructions for SaMD classification, including AI-enabled clinical decision support, aligning more closely with FDA and IMDRF frameworks. For digital health and AI MedTech sponsors, the Brazilian pathway is now substantially more predictable than it was 24 months ago.

    All three streams are happening on top of the already-operative parallel review framework under Lei 14.874, which lets sponsors submit to ANVISA and the institutional ethics review system simultaneously rather than sequentially.

    Why the Window Matters Now

    For sponsors planning a Brazilian arm of a clinical trial — or a market access registration — three strategic implications flow from the current convergence wave.

    Documentation prepared for FDA or EU MDR is increasingly leverageable in Brazil. The technical file structure, risk classification reasoning, and clinical evidence summary you build for an FDA 510(k), De Novo, or EU MDR conformity assessment now translates more directly into ANVISA’s expectations than at any prior moment. The historical penalty of duplicating documentation across regions is materially smaller in 2026 than it was in 2022.

    The window for “first to file under the new framework” is open. Regulatory teams that align Brazilian submissions with the new convergence framework now will move ahead of teams that wait for further clarification. Once a sponsor has navigated one device through the new SIUD or updated SaMD pathway, every subsequent submission moves faster.

    Post-market obligations are being modernized. The new SIUD database is not just a labeling exercise — it forms the backbone of a more sophisticated post-market surveillance regime. Sponsors who structure their data capture and adverse event tracking systems to align with the new SIUD inputs from day one save significant retrofit cost later.

    Practical Planning for the Next 12 to 18 Months

    Three actions are appropriate for any sponsor with Brazilian exposure or plans:

    • Audit your UDI strategy now. If your device class is in the early SIUD phase-in, allocate budget and labeling capacity in 2026. If your device is in a later phase, use the next 12 months to harmonize UDI assignment with the FDA UDI database and the EU EUDAMED framework so all three jurisdictions are covered with a single system.
    • Restructure your technical file with convergence in mind. The 2026 reality is that one well-organized technical file should serve FDA, EU MDR, and ANVISA submissions with mostly mechanical translation steps and only modest jurisdiction-specific addenda. If your team is still maintaining three parallel files, the next 12 months are the right window to consolidate.
    • Engage early on SaMD classification. If your device incorporates software, AI, or clinical decision support, ANVISA’s updated framework means that a pre-submission classification conversation now yields meaningfully more predictable answers than two years ago. Take advantage of that predictability before launching the trial.

    Frequently Asked Questions

    Does the new ANVISA convergence framework affect clinical trial submission timelines?
    Yes — primarily through Lei 14.874’s parallel review mechanism, which lets ANVISA and ethics committees review submissions simultaneously instead of sequentially. The practical effect is a several-week to several-month reduction in start-up timelines compared with the pre-2025 framework, depending on device complexity.

    If my device is FDA-cleared, will ANVISA accept the FDA submission as-is?
    Not as-is. ANVISA’s reliance and convergence framework reduces duplication but does not eliminate the need for a Brazil-specific submission. What it does change is that your FDA-aligned technical file, risk classification logic, and clinical evidence package now translate more directly into ANVISA expectations, with smaller jurisdiction-specific gaps to fill.

    How does the SIUD database affect sponsors who do not yet sell in Brazil?
    If you have no Brazilian commercial presence and no plans for one, SIUD does not directly apply. If you are running a clinical trial in Brazil intending to commercialize there later — or to use Brazilian data in support of a future commercial registration — building UDI alignment into your trial-stage device labeling now is materially cheaper than retrofitting it later.

    bioaccess® supports first-in-human and early-feasibility medical device trials across 10 Latin American countries, including Brazil under ANVISA’s modernized framework. Learn more at bioaccessla.com or book a strategy conversation at bioaccessla.com/book-a-meeting.

  • Brazil’s 90‑Business‑Day ANVISA Clock: A First‑in‑Human Activation Timeline for MedTech

    Brazil’s 90‑Business‑Day ANVISA Clock: A First‑in‑Human Activation Timeline for MedTech

    For MedTech founders and regulatory directors, “first patient in” is not a single milestone—it is the outcome of dozens of parallel workstreams that must converge at the right time. Brazil has become an increasingly attractive environment for early-stage studies because the country’s regulatory pathway has defined review timelines for parts of the process, including a 90-business-day window for ANVISA’s analysis of key clinical trial petitions as described by the U.S. NIH’s ClinRegs Brazil overview.

    But a fast clock on paper does not automatically translate into a fast activation in practice. Sponsors still lose weeks when ethics submissions, ANVISA dossiers, import readiness, and site enablement are treated as sequential tasks rather than an integrated program. This article provides a practical first-in-human (FIH) activation timeline for Brazil—designed for medical devices and combination products—so teams can predict the critical path, reduce avoidable rework, and protect study quality.

    Why Brazil is different for early-stage activation

    Brazil’s clinical research oversight operates as a dual system. On the regulatory side, ANVISA is responsible for clinical trial oversight, approvals, and inspections. On the ethics side, institutional Research Ethics Committees (CEPs) and the National Research Ethics Commission (CONEP) safeguard participant rights and may be required for certain studies, including some with foreign sponsorship. ClinRegs notes that clinical trials may only begin after both ethics and ANVISA approvals are in place, and that sponsors can submit in parallel rather than waiting for one decision before starting the other.

    For FIH programs, the key operational insight is that “parallel” only works if your team pre-builds the dossier and operational backbone in a way that prevents late-stage gaps. That means aligning protocol, investigator’s brochure (or device equivalent), risk management, investigational product logistics, and site readiness into one activation plan.

    A practical FIH activation timeline (week-by-week)

    The timeline below is a planning template. Your specific path will vary based on device risk class, whether the product is a device-only investigation or a drug-device combination, whether import is required, and whether CONEP review applies. Still, most FIH teams benefit from managing the activation plan as six overlapping phases.

    Phase 1 (Weeks 0–2): Activation blueprint and dossier alignment

    • Define the activation goal: first patient in, first-in-country, or first site activated—then translate it into a dated plan with owners.
    • Freeze core scientific documents: protocol, statistical approach (if applicable), investigator brochure/device technical file summary, informed consent draft, and safety monitoring plan.
    • Pre-brief sites: confirm investigator interest, feasibility, patient pool, and required imaging/lab capabilities.
    • Map the import path: determine whether investigational product import will be needed, what documents are required, and when to initiate customs planning.

    Common pitfall: teams treat feasibility as “business development,” then discover late that the site cannot execute key assessments. For FIH studies, feasibility should be treated as a protocol risk-control activity.

    Phase 2 (Weeks 2–4): Parallel submission readiness (ethics + ANVISA)

    ClinRegs indicates that clinical trial applications can be submitted in parallel in Brazil. Use that advantage. Your objective in this phase is not merely to “submit,” but to submit dossiers that survive the first pass without avoidable queries.

    • Ethics package readiness: ensure Portuguese-language materials, recruitment approach, participant protections, investigator CVs, and site documentation are complete.
    • Regulatory package readiness: align device description, risk analysis, prior testing, clinical rationale, and monitoring approach into an internally consistent narrative.
    • Operational readiness: contract templates, budget assumptions, data capture approach, and vendor onboarding plan.

    Tip: run an internal “approval simulation” meeting before submission. Ask: if the reviewer questions the risk–benefit logic, do we have a clear answer embedded in the dossier?

    Phase 3 (Weeks 4–10): Review window management and rapid-response loop

    ClinRegs describes a 90-business-day timeframe for ANVISA’s analysis of key clinical trial dossiers, with defined sponsor response windows when additional information is requested. Even with set timelines, the sponsor’s responsiveness and document discipline often determine whether the review stays on track.

    • Stand up a “question-response” war room: pre-assign technical owners (clinical, quality, regulatory, biostatistics, logistics) so questions can be addressed within days, not weeks.
    • Maintain a single source of truth: track every submitted document version and every response in a controlled repository.
    • Keep sites warm: train coordinators, initiate essential vendor qualification, and prepare for SIV scheduling so you can start immediately after approvals.

    Common pitfall: teams wait for approval before planning site initiation, then lose 2–4 weeks to avoidable scheduling and vendor delays.

    Phase 4 (Weeks 8–12): Import and investigational product readiness

    FIH programs fail more often from logistics than from science. If you need to import devices, kits, or ancillary supplies, design the import process as a parallel track, not an afterthought.

    • Confirm labeling and packaging requirements: ensure your investigational labeling supports clinical-use workflows and aligns with the protocol.
    • Build a customs-ready document pack: commercial invoice equivalents, certificates, and product descriptions that minimize ambiguity.
    • Create a buffer strategy: hold contingency inventory or stage supplies locally when feasible.

    Tip: for FIH devices, plan at least one “mock shipment” exercise or logistics rehearsal, even if it’s document-only. The point is to find gaps while time remains.

    Phase 5 (Weeks 10–14): Site initiation and first patient in

    • Run targeted SIVs: prioritize protocol-critical procedures, safety reporting, and data integrity steps.
    • Operationalize screening: define screening triggers, referral pathways, and investigator decision trees.
    • Monitor early execution: the first 1–3 patients usually reveal whether your trial design is workable in the real world.

    Common pitfall: launching without clear screening criteria and without real-time visibility into early deviations. For FIH, early deviations often signal that the trial design needs operational adjustments.

    Phase 6 (Weeks 14+): Stabilize, scale sites, and protect data quality

    • Scale site network deliberately: expand only after the first site demonstrates protocol adherence and predictable enrollment.
    • Harden the safety loop: ensure rapid reporting, investigator training, and sponsor review cadence.
    • Maintain audit readiness: document control and deviation management are not optional; they are how you preserve the value of your data for future submissions.

    Checklist: What to pre-build before you submit

    • Protocol + operational workflow map (how each visit is executed at the site)
    • Device/technology summary that is consistent across regulatory, ethics, and site materials
    • Risk management narrative that ties hazards to mitigations and monitoring
    • Import-readiness pack with clear product descriptors and shipping plan
    • Vendor onboarding plan (labs, imaging, data capture, logistics) aligned to activation dates
    • Response war room with named owners and draft response templates

    FAQ

    1) Can we submit to ethics and ANVISA at the same time in Brazil?

    Yes. ClinRegs indicates that clinical trial applications can be submitted in parallel, but trials should not start until both approvals are in place. The operational value is in reducing idle time by building parallel readiness workstreams.

    2) What typically delays first-in-human activation the most?

    In many FIH programs, delays come from late dossier inconsistencies, slow responses to reviewer questions, and underestimated import and site-startup tasks. Treat activation as a program with a critical path rather than a compliance checklist.

    3) How do we protect data quality while moving fast?

    Move fast by reducing rework—not by cutting corners. Standardize document control, train sites on protocol-critical steps, and implement real-time deviation monitoring so you can correct execution issues early.

    Educational content only. Sponsors should consult qualified regulatory and clinical research professionals for study-specific planning.

  • Select The Right Clinical Trial Site In Brazil: A Step-By-Step Guide

    <h2 id="introduction">Introduction</h2>

    <p>Choosing the right clinical trial site in Brazil is crucial for the success of your research initiatives. Navigating Brazil's evolving regulatory landscape can be daunting for sponsors. Understanding the nuances of site selection is essential for success. This guide will help you identify and evaluate potential sites while tackling the logistical and recruitment challenges you might face.</p>

    <p>So, how can you make sure your choices meet regulatory standards and boost patient recruitment in this ever-changing market?</p>

    <h2 id="understand-brazils-regulatory-framework-for-clinical-trials">Understand Brazil's Regulatory Framework for Clinical Trials</h2>

    <p>Before selecting a clinical trial site in Brazil, it is essential to grasp the regulatory landscape set by ANVISA for success. Key components include:</p>

    <ol>

    <li><a href="https://bioaccessla.com/blog/10-essential-clinical-trial-coordinator-duties-for-research-success">Approval Process</a>: <a href="https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil" rel="noopener noreferrer nofollow" target="_blank">Clinical research applications must be submitted to ANVISA</a>, which now has a strict limit of 90 business days for approval under the new regulations effective from January 1, 2025. It's vital to meticulously prepare all necessary documentation, such as the clinical study protocol and informed consent forms, in line with ANVISA's guidelines.</li>

    <li><a href="https://bioaccessla.com/blog/10-capa-corrective-action-preventive-action-strategies-for-clinical-research">Compliance Requirements</a>: Studies must adhere to ICH-GCP (International Council for Harmonisation – Good Clinical Practice) standards, crucial for protecting the rights, safety, and well-being of participants. Following these standards is not just a regulatory necessity; it also boosts the credibility of the data collected.</li>

    <li><a href="https://bioaccessla.com/blog/10-essential-features-of-clinical-trial-data-software-for-success">Ethics Committee Approval</a>: In addition to ANVISA, studies must receive endorsement from a local ethics committee (Comitê de Ética em Pesquisa – CEP). This process evaluates the ethical aspects of the study, ensuring participant safety and adherence to ethical standards.</li>

    <li>Documentation: Thorough documentation is essential for the review processes of both ANVISA and the ethics committee. It includes preclinical data, study protocols, and investigator qualifications, which must be thoroughly prepared to facilitate a smooth approval process.</li>

    <li>Regulatory Changes: Stay informed about <a href="https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil" rel="noopener noreferrer nofollow" target="_blank">recent legislative changes, such as Law No. 14.874/2024</a>, which aims to streamline the approval process and reduce bureaucratic hurdles. Grasping these transformations can offer a strategic edge in location selection and study execution, enabling quicker commencement of research activities.</li>

    </ol>

    <p>By mastering these regulatory nuances, sponsors position themselves for a more efficient and effective research journey at a clinical trial site in Brazil.</p>

    <p><img alt="This flowchart guides you through the essential steps for navigating the regulatory landscape for clinical trials in Brazil. Each box represents a key component of the process, and the arrows show how they connect and flow into one another." src="https://images.tely.ai/telyai/rtsjkopf-this-flowchart-guides-you-through-the-essential-steps-for-navigating-the-regulatory-landscape-for-clinical-trials-in-brazil-each-box-represents-a-key-component-of-the-process-and-the-arrows-show-how-they-connect-and-flow-into-one-another.webp" title="This flowchart guides you through the essential steps for navigating the regulatory landscape for clinical trials in Brazil. Each box represents a key component of the process, and the arrows show how they connect and flow into one another."/></p>

    <h2 id="identify-and-evaluate-potential-clinical-trial-sites">Identify and Evaluate Potential Clinical Trial Sites</h2>

    <p>Identifying the right <a href="https://bioaccessla.com/br">clinical trial site Brazil</a> is a complex challenge that requires a strategic approach to ensure successful outcomes. Here are the essential steps to follow:</p>

    <ol>

    <li>

    <p>Define Selection Criteria: Establish clear criteria based on the trial's objectives, including:</p>

    <ul>

    <li>Patient Population: Assess the prevalence of the condition being studied within the site's catchment area. Higher prevalence rates can significantly enhance recruitment efforts, making it crucial to evaluate <a href="https://bioaccessla.com/blog/10-key-compliance-insights-for-class-1-devices-you-need-now">local health statistics</a>. For example, <a href="https://expertmarketresearch.com/reports/brazil-clinical-trials-market" rel="noopener noreferrer nofollow" target="_blank">Brazil is expected to report over 704,000 new cancer cases each year from 2023 to 2025</a>, emphasizing the significance of focusing on areas with appropriate patient demographics.</li>

    <li>Infrastructure Evaluation: Assess the facilities, equipment, and staff qualifications of the location. Ensure that the location has the essential resources, including advanced medical technology and skilled personnel, to conduct the study efficiently.</li>

    <li>Regulatory Experience: Seek locations with a proven track record of <a href="https://lek.com/insights/life-sciences-pharma/unlocking-brazils-clinical-trial-opportunity-strategic-roadmap" rel="noopener noreferrer nofollow" target="_blank">compliance with ANVISA regulations and ICH-GCP standards</a>. This experience is crucial for ensuring that the study complies with all regulatory standards and can promote smoother approval processes, particularly since the clinical trial site Brazil may encounter an approval process that extends up to 18 months.</li>

    </ul>

    </li>

    <li>

    <p>Conduct Feasibility Studies: Perform thorough <a href="https://bioaccessla.com/blog/10-key-insights-on-eap-regulations-for-bulgarias-clinical-trials">feasibility assessments</a> to gauge the site's capability to meet the study's requirements. This includes:</p>

    <ul>

    <li>Site Visits: Conduct on-site evaluations to observe the facilities firsthand and meet the research team, ensuring they align with the trial's needs.</li>

    <li>Interviews with Investigators: Discuss their experience, <a href="https://bioaccessla.com/blog/10-benefits-of-clinical-trial-remote-monitoring-for-research-directors">patient recruitment strategies</a>, and commitment to the trial. Understanding their approach can provide insights into potential challenges and opportunities.</li>

    </ul>

    </li>

    <li>

    <p>Utilize Local Networks: Leverage local CROs, such as bioaccess®, to identify pre-qualified locations. These organizations often have established connections with locations and can offer valuable insights into their capabilities, enhancing the selection process. bioaccess® specializes in accelerating Phase I <a href="https://bioaccessla.com/br/services">first-in-human studies</a> in Latin America, providing 4-8 week ethics approvals and FDA/EMA-ready clinical data, which is essential for prompt execution.</p>

    </li>

    <li>

    <p>Review Historical Performance: Examine the past performance of potential locations in earlier evaluations, concentrating on recruitment rates, data quality, and adherence to timelines. This data can help predict future performance and identify reliable partners.</p>

    </li>

    <li>

    <p>Engage Stakeholders: Involve key participants, including investigators and personnel at the locations, in the selection process to ensure alignment with the study's goals and expectations. Their input can be invaluable in refining the selection criteria and ensuring a collaborative approach.</p>

    </li>

    </ol>

    <p>By adhering to these procedures, failing to select the right research locations could jeopardize timelines and <a href="https://bioaccessla.com/cart">regulatory compliance</a>, ultimately hindering the introduction of vital therapies to the market. This strategy boosts the likelihood of hitting recruitment targets while keeping regulatory standards in check, paving the way for vital therapies to reach the market more smoothly. Considering that <a href="https://fortunebusinessinsights.com/brazil-clinical-trials-market-112310" rel="noopener noreferrer nofollow" target="_blank">the Brazilian market for healthcare studies is anticipated to achieve a projected income of USD 443.5 million by 2032</a>, the importance of selecting the right clinical trial site Brazil cannot be emphasized enough.</p>

    <p><img alt="This flowchart outlines the steps to identify and evaluate clinical trial sites. Each box represents a key step in the process, and the arrows show the order in which to follow them. Start at the top and move down to ensure you cover all necessary aspects for successful site selection." src="https://images.tely.ai/telyai/wgxvvhad-this-flowchart-outlines-the-steps-to-identify-and-evaluate-clinical-trial-sites-each-box-represents-a-key-step-in-the-process-and-the-arrows-show-the-order-in-which-to-follow-them-start-at-the-top-and-move-down-to-ensure-you-cover-all-necessary-aspects-for-successful-site-selection.webp" title="This flowchart outlines the steps to identify and evaluate clinical trial sites. Each box represents a key step in the process, and the arrows show the order in which to follow them. Start at the top and move down to ensure you cover all necessary aspects for successful site selection."/></p>

    <h2 id="assess-logistics-and-patient-recruitment-strategies">Assess Logistics and Patient Recruitment Strategies</h2>

    <p>Identifying potential clinical research locations is just the beginning; the real challenge lies in logistics and patient recruitment. Let’s explore some key factors to consider:</p>

    <ol>

    <li>

    <p>Logistical Considerations: Evaluate the <a href="https://bioaccessla.com/blog/10-common-ethics-submission-mistakes-in-australia-to-avoid">logistical capabilities of each site</a>, including:</p>

    <ul>

    <li>Supply Chain Management: Ensure the site can effectively manage the supply of investigational products, including storage and distribution requirements, in compliance with ICH-GCP standards.</li>

    <li>Transportation: Assess the accessibility of the location for both patients and research staff, considering transportation options for participants, especially in rural areas where access might be limited.</li>

    <li><a href="https://bioaccessla.com/blog/10-benefits-of-electronic-data-capture-for-clinical-trials">Data Management Systems</a>: Confirm that the site has robust data management systems in place to ensure accurate and timely data collection and reporting, facilitating <a href="https://bioaccessla.com/market-access">FDA-bridgeable data acceptance</a> for regulatory submissions.</li>

    </ul>

    </li>

    <li>

    <p><a href="https://bioaccessla.com/es/services">Patient Recruitment Strategies</a>: Develop effective <a href="https://openclinica.com/blog/seven-patient-recruitment-best-practices-used-by-leading-research-studies" rel="noopener noreferrer nofollow" target="_blank">patient recruitment strategies tailored to the local context</a>:</p>

    <ul>

    <li><a href="https://openclinica.com/blog/seven-patient-recruitment-best-practices-used-by-leading-research-studies" rel="noopener noreferrer nofollow" target="_blank">Community Engagement</a>: Build relationships with local healthcare providers and community organizations to raise awareness about the trial and its benefits, fostering trust and collaboration that can enhance recruitment outcomes.</li>

    <li>Digital Outreach: Utilize social media and online platforms to reach potential participants, particularly younger demographics who may be more engaged online, thereby expanding the pool of candidates.</li>

    <li>Patient Advocacy Groups: Collaborate with <a href="https://bioaccessla.com/blog/10-benefits-of-combining-regulatory-and-ethics-approval-in-australia">patient advocacy organizations</a> to tap into their networks, leveraging their influence to enhance enrollment efforts and ensure that patient needs are respected.</li>

    </ul>

    </li>

    <li>

    <p>Cultural Considerations: Understand the cultural nuances that may affect patient participation. Customize outreach messages to connect with the local community, addressing any issues or misunderstandings about studies, which can greatly influence enrollment rates.</p>

    </li>

    <li>

    <p>Consider providing incentives for involvement, such as transportation reimbursement or compensation for time spent in the study, to improve enrollment rates. This approach acknowledges the value of participants' time and can lead to higher enrollment and retention rates.</p>

    </li>

    </ol>

    <p>When you thoroughly evaluate logistics and implement effective patient recruitment strategies, sponsors can ensure that their chosen <a href="https://grandviewresearch.com/horizon/outlook/clinical-trial-patient-recruitment-services-market/brazil" rel="noopener noreferrer nofollow" target="_blank">clinical trial site in Brazil is well-equipped to enroll participants efficiently</a> and conduct studies successfully, capitalizing on the expanding market for medical research in Brazil, projected to reach USD 1,033.6 million by 2033. Without a strategic approach to logistics and recruitment, even the best research locations may fall short of their potential.</p>

    <p><img alt="This mindmap starts with the main topic in the center and branches out into key areas to consider for successful clinical trials. Each branch represents a different aspect of logistics and recruitment, with further details provided in the sub-branches. Follow the connections to see how each factor contributes to the overall strategy." src="https://images.tely.ai/telyai/zskpovqz-this-mindmap-starts-with-the-main-topic-in-the-center-and-branches-out-into-key-areas-to-consider-for-successful-clinical-trials-each-branch-represents-a-different-aspect-of-logistics-and-recruitment-with-further-details-provided-in-the-sub-branches-follow-the-connections-to-see-how-each-factor-contributes-to-the-overall-strategy.webp" title="This mindmap starts with the main topic in the center and branches out into key areas to consider for successful clinical trials. Each branch represents a different aspect of logistics and recruitment, with further details provided in the sub-branches. Follow the connections to see how each factor contributes to the overall strategy."/></p>

    <h2 id="establish-communication-and-collaboration-with-the-site">Establish Communication and Collaboration with the Site</h2>

    <p><a href="https://bioaccessla.com/br/solutions">Effective communication</a> is not just beneficial; it is essential for the success of any clinical trial site in Brazil. Follow these <a href="https://bioaccessla.com/blog/10-benefits-of-electronic-data-capture-for-clinical-research">best practices to ensure your study runs smoothly</a>:</p>

    <ol>

    <li>Initial Meetings: Conduct <a href="https://globalforum.diaglobal.org/issue/june-2024/back-to-communication-basics-reducing-site-burden-and-establishing-a-sponsor-cro-of-choice-relationship-with-investigative-sites" rel="noopener noreferrer nofollow" target="_blank">preliminary meetings with site personnel</a> to discuss study objectives, expectations, and timelines. Make sure everyone is aligned on the goals and responsibilities of the study.</li>

    <li><a href="https://careers.iconplc.com/blogs/2024-12/communication-strategies-for-sites-and-sponsors" rel="noopener noreferrer nofollow" target="_blank">Regular Updates</a>: Consider scheduling weekly or bi-weekly meetings, tailored to the complexity of your study, to keep everyone on track. Regular check-ins help monitor progress, address challenges, and provide necessary support.</li>

    <li>Utilize Technology: Leverage technology to facilitate communication, such as project management tools and secure messaging platforms. Using these tools can really boost collaboration, making sure everyone stays in the loop with the latest updates.</li>

    <li>Feedback Mechanisms: Establish <a href="https://globalforum.diaglobal.org/issue/june-2024/back-to-communication-basics-reducing-site-burden-and-establishing-a-sponsor-cro-of-choice-relationship-with-investigative-sites" rel="noopener noreferrer nofollow" target="_blank">feedback mechanisms to encourage open communication</a>. Create an environment where staff feel comfortable sharing concerns or suggestions for enhancement.</li>

    <li><a href="https://bioaccessla.com/blog/10-essential-clinical-trial-agreement-requirements-in-serbia">Training and Support</a>: Offer instruction and continuous assistance to personnel to ensure they are adequately prepared to execute the study in accordance with protocol. This can include training on data collection methods, compliance requirements, and <a href="https://bioaccessla.com/testimonials">patient engagement strategies</a>.</li>

    <li><a href="https://bioaccessla.com/blog/10-croatia-ethics-committee-so-ps-every-sponsor-must-know">Celebrate Milestones</a>: Acknowledge and honor achievements reached during the study to promote a positive working relationship and inspire personnel.</li>

    </ol>

    <p>Without effective communication, misunderstandings can derail the study's progress. When sponsors prioritize strong communication and collaboration with the <a href="https://bioaccessla.com/br/about">clinical trial site Brazil</a>, they not only enhance the likelihood of success but also ensure that the study runs smoothly and efficiently.</p>

    <p><img alt="This flowchart outlines the steps to improve communication and collaboration at a clinical trial site. Each box represents a key practice, and the arrows show how these practices connect to create a successful communication strategy." src="https://images.tely.ai/telyai/gjciscev-this-flowchart-outlines-the-steps-to-improve-communication-and-collaboration-at-a-clinical-trial-site-each-box-represents-a-key-practice-and-the-arrows-show-how-these-practices-connect-to-create-a-successful-communication-strategy.webp" title="This flowchart outlines the steps to improve communication and collaboration at a clinical trial site. Each box represents a key practice, and the arrows show how these practices connect to create a successful communication strategy."/></p>

    <h2 id="conclusion">Conclusion</h2>

    <p>Selecting the right clinical trial site in Brazil is not just important; it can make or break the success of your research initiatives. Understanding the regulatory framework and evaluating potential sites are essential. Implementing effective communication strategies is equally crucial. By focusing on these elements, sponsors can significantly enhance their chances of conducting successful trials that meet regulatory standards and achieve operational excellence.</p>

    <p>The article emphasizes several key factors that contribute to successful site selection. First, a thorough understanding of Brazil's regulatory landscape, including compliance with ANVISA and ICH-GCP standards, is crucial. Second, the importance of defining selection criteria, conducting feasibility studies, and leveraging local networks cannot be overstated. Finally, establishing strong communication and collaboration with site personnel ensures that all stakeholders are aligned and can navigate challenges effectively.</p>

    <p>As Brazil's prominence as a hub for clinical trials grows, how can stakeholders adopt a strategic approach to site selection? By prioritizing regulatory compliance, logistical efficiency, and effective patient recruitment strategies, researchers can capitalize on Brazil's unique advantages for early-stage clinical trials. This proactive approach will not only streamline the trial process but also contribute to the timely introduction of innovative therapies to the market, ultimately benefiting both patients and the broader healthcare landscape.</p>

    <p><iframe frameborder="0" height="300px" loading="lazy" src="https://iframe.tely.ai/cta/eyJhcnRpY2xlX2lkIjogIjY5ZjNlZDFhOTJiYTZiMzkyM2RhOGQ3OCIsICJjb21wYW55X2lkIjogIjY2OTk4NmYwMzM1YWQwNDI3ZTVmNTdlMyIsICJpbmRleCI6IG51bGwsICJ0eXBlIjogImFydGljbGUifQ==" width="100%"></iframe></p>

    <h2 id="frequently-asked-questions">Frequently Asked Questions</h2>

    <p><strong>What is the approval process for clinical trials in Brazil?</strong></p>

    <p>Clinical research applications must be submitted to ANVISA, which has a strict limit of 90 business days for approval under new regulations effective from January 1, 2025. It is crucial to prepare all necessary documentation, including the clinical study protocol and informed consent forms, according to ANVISA's guidelines.</p>

    <p><strong>What compliance requirements must be met for clinical trials in Brazil?</strong></p>

    <p>Studies must comply with ICH-GCP (International Council for Harmonisation – Good Clinical Practice) standards, which are essential for protecting the rights, safety, and well-being of participants. Adhering to these standards not only fulfills regulatory requirements but also enhances the credibility of the collected data.</p>

    <p><strong>Is ethics committee approval required for clinical trials in Brazil?</strong></p>

    <p>Yes, in addition to ANVISA approval, clinical trials must receive endorsement from a local ethics committee (Comitê de Ética em Pesquisa – CEP). This committee evaluates the ethical aspects of the study to ensure participant safety and adherence to ethical standards.</p>

    <p><strong>What documentation is required for the approval process in Brazil?</strong></p>

    <p>Thorough documentation is essential for both ANVISA and the ethics committee review processes. This includes preclinical data, study protocols, and investigator qualifications, all of which must be meticulously prepared to facilitate a smooth approval process.</p>

    <p><strong>Are there any recent regulatory changes affecting clinical trials in Brazil?</strong></p>

    <p>Yes, recent legislative changes, such as Law No. 14.874/2024, aim to streamline the approval process and reduce bureaucratic hurdles. Staying informed about these changes can provide a strategic advantage in site selection and study execution, allowing for quicker commencement of research activities.</p>

    <p><strong>How can understanding Brazil's regulatory framework benefit sponsors of clinical trials?</strong></p>

    <p>By mastering the regulatory nuances in Brazil, sponsors can position themselves for a more efficient and effective research journey at clinical trial sites, ultimately enhancing the speed and success of their early-stage clinical trials.</p>

    <h2 id="list-of-sources">List of Sources</h2>

    <ol>

    <li>Understand Brazil's Regulatory Framework for Clinical Trials

    <ul>

    <li>Brazil Just Changed The Rules For Clinical Trial Approvals — What Sponsors Need To Know | bioaccess® (https://bioaccessla.com/blog/brazil-anvisa-parallel-review-clinical-trial-approvals-2026)</li>

    <li>Brazil Clinical Trials Market Size, Share | Analysis Report [2032] (https://fortunebusinessinsights.com/brazil-clinical-trials-market-112310)</li>

    <li>Brazil Clinical Trials Market Size &amp; Outlook, 2033 (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil)</li>

    </ul>

    </li>

    <li>Identify and Evaluate Potential Clinical Trial Sites

    <ul>

    <li>Brazil Clinical Trials Market Size, Share | Analysis Report [2032] (https://fortunebusinessinsights.com/brazil-clinical-trials-market-112310)</li>

    <li>Brazil Clinical Trials Market Size &amp; Outlook, 2033 (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil)</li>

    <li>Unlocking Brazil’s Clinical Trial Opportunity: A Strategic Roadmap for Healthcare Leaders (https://lek.com/insights/life-sciences-pharma/unlocking-brazils-clinical-trial-opportunity-strategic-roadmap)</li>

    <li>Brazil Clinical Trials Market Size &amp; Future Growth 2035 (https://expertmarketresearch.com/reports/brazil-clinical-trials-market)</li>

    <li>Patient Engagement Quotes: For Every Purpose &amp; Audience (https://nclusiv.co.uk/edi-consulting/f/patient-engagement-quotes-for-every-purpose-audience)</li>

    </ul>

    </li>

    <li>Assess Logistics and Patient Recruitment Strategies

    <ul>

    <li>Brazil Clinical Trials Market Size &amp; Outlook, 2033 (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil)</li>

    <li>10 Inspiring Patient Experience Quotes | Relias (https://relias.com/blog/patient-experience-quotes)</li>

    <li>Brazil Clinical Trial Patient Recruitment Services Market Size &amp; Outlook, 2033 (https://grandviewresearch.com/horizon/outlook/clinical-trial-patient-recruitment-services-market/brazil)</li>

    <li>Seven Best Practices For Clinical Trial Patient Recruitment (https://openclinica.com/blog/seven-patient-recruitment-best-practices-used-by-leading-research-studies)</li>

    </ul>

    </li>

    <li>Establish Communication and Collaboration with the Site

    <ul>

    <li>Top 5 Alarming Statistics on Clinical Trial Site Selection (https://biobostonconsulting.com/top-5-alarming-statistics-you-must-know-about-clinical-trial-site-selection)</li>

    <li>Communication Strategies for Sites and Sponsors in Clinical Research | ICON news and blogs (https://careers.iconplc.com/blogs/2024-12/communication-strategies-for-sites-and-sponsors)</li>

    <li>Back to (Communication) Basics: Reducing Site Burden and Establishing a Sponsor/CRO-of-Choice Relationship with Investigative Sites (https://globalforum.diaglobal.org/issue/june-2024/back-to-communication-basics-reducing-site-burden-and-establishing-a-sponsor-cro-of-choice-relationship-with-investigative-sites)</li>

    <li>25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)</li>

    </ul>

    </li>

    </ol>

    <script type="application/ld+json">{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "What is the approval process for clinical trials in Brazil?", "acceptedAnswer": {"@type": "Answer", "text": "Clinical research applications must be submitted to ANVISA, which has a strict limit of 90 business days for approval under new regulations effective from January 1, 2025. It is crucial to prepare all necessary documentation, including the clinical study protocol and informed consent forms, according to ANVISA's guidelines."}}, {"@type": "Question", "name": "What compliance requirements must be met for clinical trials in Brazil?", "acceptedAnswer": {"@type": "Answer", "text": "Studies must comply with ICH-GCP (International Council for Harmonisation – Good Clinical Practice) standards, which are essential for protecting the rights, safety, and well-being of participants. Adhering to these standards not only fulfills regulatory requirements but also enhances the credibility of the collected data."}}, {"@type": "Question", "name": "Is ethics committee approval required for clinical trials in Brazil?", "acceptedAnswer": {"@type": "Answer", "text": "Yes, in addition to ANVISA approval, clinical trials must receive endorsement from a local ethics committee (Comitê de Ética em Pesquisa – CEP). This committee evaluates the ethical aspects of the study to ensure participant safety and adherence to ethical standards."}}, {"@type": "Question", "name": "What documentation is required for the approval process in Brazil?", "acceptedAnswer": {"@type": "Answer", "text": "Thorough documentation is essential for both ANVISA and the ethics committee review processes. This includes preclinical data, study protocols, and investigator qualifications, all of which must be meticulously prepared to facilitate a smooth approval process."}}, {"@type": "Question", "name": "Are there any recent regulatory changes affecting clinical trials in Brazil?", "acceptedAnswer": {"@type": "Answer", "text": "Yes, recent legislative changes, such as Law No. 14.874/2024, aim to streamline the approval process and reduce bureaucratic hurdles. Staying informed about these changes can provide a strategic advantage in site selection and study execution, allowing for quicker commencement of research activities."}}, {"@type": "Question", "name": "How can understanding Brazil's regulatory framework benefit sponsors of clinical trials?", "acceptedAnswer": {"@type": "Answer", "text": "By mastering the regulatory nuances in Brazil, sponsors can position themselves for a more efficient and effective research journey at clinical trial sites, ultimately enhancing the speed and success of their early-stage clinical trials."}}]}</script><script type="application/ld+json">{"@context": "https://schema.org", "@type": "BlogPosting", "headline": "Select the Right Clinical Trial Site in Brazil: A Step-by-Step Guide", "description": "Discover how to select the ideal clinical trial site in Brazil for effective research outcomes.", "datePublished": "2026-05-01T00:00:26.170000", "dateModified": "2026-05-02T04:56:20.981444+00:00", "articleBody": "## IntroductionnChoosing the right clinical trial site in Brazil is crucial for the success of your research initiatives. Navigating Brazil's evolving regulatory landscape can be daunting for sponsors. Understanding the nuances of site selection is essential for success. This guide will help you identify and evaluate potential sites while tackling the logistical and recruitment challenges you might face. nnSo, how can you make sure your choices meet regulatory standards and boost patient recruitment in this ever-changing market?nn## Understand Brazil's Regulatory Framework for Clinical TrialsnnBefore selecting a clinical trial site in Brazil, it is essential to grasp the regulatory landscape set by ANVISA for success. Key components include:nn1. [Approval Process](https://bioaccessla.com/blog/10-essential-clinical-trial-coordinator-duties-for-research-success): [Clinical research applications must be submitted to ANVISA](https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil), which now has a strict limit of 90 business days for approval under the new regulations effective from January 1, 2025. It's vital to meticulously prepare all necessary documentation, such as the clinical study protocol and informed consent forms, in line with ANVISA's guidelines.n2. [Compliance Requirements](https://bioaccessla.com/blog/10-capa-corrective-action-preventive-action-strategies-for-clinical-research): Studies must adhere to ICH-GCP (International Council for Harmonisation – Good Clinical Practice) standards, crucial for protecting the rights, safety, and well-being of participants. Following these standards is not just a regulatory necessity; it also boosts the credibility of the data collected.n3. [Ethics Committee Approval](https://bioaccessla.com/blog/10-essential-features-of-clinical-trial-data-software-for-success): In addition to ANVISA, studies must receive endorsement from a local ethics committee (Comitê de Ética em Pesquisa – CEP). This process evaluates the ethical aspects of the study, ensuring participant safety and adherence to ethical standards.n4. Documentation: Thorough documentation is essential for the review processes of both ANVISA and the ethics committee. It includes preclinical data, study protocols, and investigator qualifications, which must be thoroughly prepared to facilitate a smooth approval process.n5. Regulatory Changes: Stay informed about [recent legislative changes, such as Law No. 14.874/2024](https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil), which aims to streamline the approval process and reduce bureaucratic hurdles. Grasping these transformations can offer a strategic edge in location selection and study execution, enabling quicker commencement of research activities.nnBy mastering these regulatory nuances, sponsors position themselves for a more efficient and effective research journey at a clinical trial site in Brazil.nn![This flowchart guides you through the essential steps for navigating the regulatory landscape for clinical trials in Brazil. Each box represents a key component of the process, and the arrows show how they connect and flow into one another.](https://images.tely.ai/telyai/rtsjkopf-this-flowchart-guides-you-through-the-essential-steps-for-navigating-the-regulatory-landscape-for-clinical-trials-in-brazil-each-box-represents-a-key-component-of-the-process-and-the-arrows-show-how-they-connect-and-flow-into-one-another.webp "This flowchart guides you through the essential steps for navigating the regulatory landscape for clinical trials in Brazil. Each box represents a key component of the process, and the arrows show how they connect and flow into one another.")nn## Identify and Evaluate Potential Clinical Trial SitesnnIdentifying the right [clinical trial site Brazil](https://bioaccessla.com/br) is a complex challenge that requires a strategic approach to ensure successful outcomes. Here are the essential steps to follow:nn1. Define Selection Criteria: Establish clear criteria based on the trial's objectives, including:nn   – Patient Population: Assess the prevalence of the condition being studied within the site's catchment area. Higher prevalence rates can significantly enhance recruitment efforts, making it crucial to evaluate [local health statistics](https://bioaccessla.com/blog/10-key-compliance-insights-for-class-1-devices-you-need-now). For example, [Brazil is expected to report over 704,000 new cancer cases each year from 2023 to 2025](https://expertmarketresearch.com/reports/brazil-clinical-trials-market), emphasizing the significance of focusing on areas with appropriate patient demographics.n   – Infrastructure Evaluation: Assess the facilities, equipment, and staff qualifications of the location. Ensure that the location has the essential resources, including advanced medical technology and skilled personnel, to conduct the study efficiently.n   – Regulatory Experience: Seek locations with a proven track record of [compliance with ANVISA regulations and ICH-GCP standards](https://lek.com/insights/life-sciences-pharma/unlocking-brazils-clinical-trial-opportunity-strategic-roadmap). This experience is crucial for ensuring that the study complies with all regulatory standards and can promote smoother approval processes, particularly since the clinical trial site Brazil may encounter an approval process that extends up to 18 months.n2. Conduct Feasibility Studies: Perform thorough [feasibility assessments](https://bioaccessla.com/blog/10-key-insights-on-eap-regulations-for-bulgarias-clinical-trials) to gauge the site's capability to meet the study's requirements. This includes:nn   – Site Visits: Conduct on-site evaluations to observe the facilities firsthand and meet the research team, ensuring they align with the trial's needs.n   – Interviews with Investigators: Discuss their experience, [patient recruitment strategies](https://bioaccessla.com/blog/10-benefits-of-clinical-trial-remote-monitoring-for-research-directors), and commitment to the trial. Understanding their approach can provide insights into potential challenges and opportunities.n3. Utilize Local Networks: Leverage local CROs, such as bioaccess®, to identify pre-qualified locations. These organizations often have established connections with locations and can offer valuable insights into their capabilities, enhancing the selection process. bioaccess® specializes in accelerating Phase I [first-in-human studies](https://bioaccessla.com/br/services) in Latin America, providing 4-8 week ethics approvals and FDA/EMA-ready clinical data, which is essential for prompt execution.n4. Review Historical Performance: Examine the past performance of potential locations in earlier evaluations, concentrating on recruitment rates, data quality, and adherence to timelines. This data can help predict future performance and identify reliable partners.n5. Engage Stakeholders: Involve key participants, including investigators and personnel at the locations, in the selection process to ensure alignment with the study's goals and expectations. Their input can be invaluable in refining the selection criteria and ensuring a collaborative approach.nnBy adhering to these procedures, failing to select the right research locations could jeopardize timelines and [regulatory compliance](https://bioaccessla.com/cart), ultimately hindering the introduction of vital therapies to the market. This strategy boosts the likelihood of hitting recruitment targets while keeping regulatory standards in check, paving the way for vital therapies to reach the market more smoothly. Considering that [the Brazilian market for healthcare studies is anticipated to achieve a projected income of USD 443.5 million by 2032](https://fortunebusinessinsights.com/brazil-clinical-trials-market-112310), the importance of selecting the right clinical trial site Brazil cannot be emphasized enough.nn![This flowchart outlines the steps to identify and evaluate clinical trial sites. Each box represents a key step in the process, and the arrows show the order in which to follow them. Start at the top and move down to ensure you cover all necessary aspects for successful site selection.](https://images.tely.ai/telyai/wgxvvhad-this-flowchart-outlines-the-steps-to-identify-and-evaluate-clinical-trial-sites-each-box-represents-a-key-step-in-the-process-and-the-arrows-show-the-order-in-which-to-follow-them-start-at-the-top-and-move-down-to-ensure-you-cover-all-necessary-aspects-for-successful-site-selection.webp "This flowchart outlines the steps to identify and evaluate clinical trial sites. Each box represents a key step in the process, and the arrows show the order in which to follow them. Start at the top and move down to ensure you cover all necessary aspects for successful site selection.")nn## Assess Logistics and Patient Recruitment StrategiesnnIdentifying potential clinical research locations is just the beginning; the real challenge lies in logistics and patient recruitment. Let’s explore some key factors to consider:nn1. Logistical Considerations: Evaluate the [logistical capabilities of each site](https://bioaccessla.com/blog/10-common-ethics-submission-mistakes-in-australia-to-avoid), including:nn   – Supply Chain Management: Ensure the site can effectively manage the supply of investigational products, including storage and distribution requirements, in compliance with ICH-GCP standards.n   – Transportation: Assess the accessibility of the location for both patients and research staff, considering transportation options for participants, especially in rural areas where access might be limited.n   – [Data Management Systems](https://bioaccessla.com/blog/10-benefits-of-electronic-data-capture-for-clinical-trials): Confirm that the site has robust data management systems in place to ensure accurate and timely data collection and reporting, facilitating [FDA-bridgeable data acceptance](https://bioaccessla.com/market-access) for regulatory submissions.n2. [Patient Recruitment Strategies](https://bioaccessla.com/es/services): Develop effective [patient recruitment strategies tailored to the local context](https://openclinica.com/blog/seven-patient-recruitment-best-practices-used-by-leading-research-studies):nn   – [Community Engagement](https://openclinica.com/blog/seven-patient-recruitment-best-practices-used-by-leading-research-studies): Build relationships with local healthcare providers and community organizations to raise awareness about the trial and its benefits, fostering trust and collaboration that can enhance recruitment outcomes.n   – Digital Outreach: Utilize social media and online platforms to reach potential participants, particularly younger demographics who may be more engaged online, thereby expanding the pool of candidates.n   – Patient Advocacy Groups: Collaborate with [patient advocacy organizations](https://bioaccessla.com/blog/10-benefits-of-combining-regulatory-and-ethics-approval-in-australia) to tap into their networks, leveraging their influence to enhance enrollment efforts and ensure that patient needs are respected.n3. Cultural Considerations: Understand the cultural nuances that may affect patient participation. Customize outreach messages to connect with the local community, addressing any issues or misunderstandings about studies, which can greatly influence enrollment rates.n4. Consider providing incentives for involvement, such as transportation reimbursement or compensation for time spent in the study, to improve enrollment rates. This approach acknowledges the value of participants' time and can lead to higher enrollment and retention rates.nnWhen you thoroughly evaluate logistics and implement effective patient recruitment strategies, sponsors can ensure that their chosen [clinical trial site in Brazil is well-equipped to enroll participants efficiently](https://grandviewresearch.com/horizon/outlook/clinical-trial-patient-recruitment-services-market/brazil) and conduct studies successfully, capitalizing on the expanding market for medical research in Brazil, projected to reach USD 1,033.6 million by 2033. Without a strategic approach to logistics and recruitment, even the best research locations may fall short of their potential.nn![This mindmap starts with the main topic in the center and branches out into key areas to consider for successful clinical trials. Each branch represents a different aspect of logistics and recruitment, with further details provided in the sub-branches. Follow the connections to see how each factor contributes to the overall strategy.](https://images.tely.ai/telyai/zskpovqz-this-mindmap-starts-with-the-main-topic-in-the-center-and-branches-out-into-key-areas-to-consider-for-successful-clinical-trials-each-branch-represents-a-different-aspect-of-logistics-and-recruitment-with-further-details-provided-in-the-sub-branches-follow-the-connections-to-see-how-each-factor-contributes-to-the-overall-strategy.webp "This mindmap starts with the main topic in the center and branches out into key areas to consider for successful clinical trials. Each branch represents a different aspect of logistics and recruitment, with further details provided in the sub-branches. Follow the connections to see how each factor contributes to the overall strategy.")nn## Establish Communication and Collaboration with the Sitenn[Effective communication](https://bioaccessla.com/br/solutions) is not just beneficial; it is essential for the success of any clinical trial site in Brazil. Follow these [best practices to ensure your study runs smoothly](https://bioaccessla.com/blog/10-benefits-of-electronic-data-capture-for-clinical-research):nn1. Initial Meetings: Conduct [preliminary meetings with site personnel](https://globalforum.diaglobal.org/issue/june-2024/back-to-communication-basics-reducing-site-burden-and-establishing-a-sponsor-cro-of-choice-relationship-with-investigative-sites) to discuss study objectives, expectations, and timelines. Make sure everyone is aligned on the goals and responsibilities of the study.n2. [Regular Updates](https://careers.iconplc.com/blogs/2024-12/communication-strategies-for-sites-and-sponsors): Consider scheduling weekly or bi-weekly meetings, tailored to the complexity of your study, to keep everyone on track. Regular check-ins help monitor progress, address challenges, and provide necessary support.n3. Utilize Technology: Leverage technology to facilitate communication, such as project management tools and secure messaging platforms. Using these tools can really boost collaboration, making sure everyone stays in the loop with the latest updates.n4. Feedback Mechanisms: Establish [feedback mechanisms to encourage open communication](https://globalforum.diaglobal.org/issue/june-2024/back-to-communication-basics-reducing-site-burden-and-establishing-a-sponsor-cro-of-choice-relationship-with-investigative-sites). Create an environment where staff feel comfortable sharing concerns or suggestions for enhancement.n5. [Training and Support](https://bioaccessla.com/blog/10-essential-clinical-trial-agreement-requirements-in-serbia): Offer instruction and continuous assistance to personnel to ensure they are adequately prepared to execute the study in accordance with protocol. This can include training on data collection methods, compliance requirements, and [patient engagement strategies](https://bioaccessla.com/testimonials).n6. [Celebrate Milestones](https://bioaccessla.com/blog/10-croatia-ethics-committee-so-ps-every-sponsor-must-know): Acknowledge and honor achievements reached during the study to promote a positive working relationship and inspire personnel.nnWithout effective communication, misunderstandings can derail the study's progress. When sponsors prioritize strong communication and collaboration with the [clinical trial site Brazil](https://bioaccessla.com/br/about), they not only enhance the likelihood of success but also ensure that the study runs smoothly and efficiently.nn![This flowchart outlines the steps to improve communication and collaboration at a clinical trial site. Each box represents a key practice, and the arrows show how these practices connect to create a successful communication strategy.](https://images.tely.ai/telyai/gjciscev-this-flowchart-outlines-the-steps-to-improve-communication-and-collaboration-at-a-clinical-trial-site-each-box-represents-a-key-practice-and-the-arrows-show-how-these-practices-connect-to-create-a-successful-communication-strategy.webp "This flowchart outlines the steps to improve communication and collaboration at a clinical trial site. Each box represents a key practice, and the arrows show how these practices connect to create a successful communication strategy.")nn## ConclusionnSelecting the right clinical trial site in Brazil is not just important; it can make or break the success of your research initiatives. Understanding the regulatory framework and evaluating potential sites are essential. Implementing effective communication strategies is equally crucial. By focusing on these elements, sponsors can significantly enhance their chances of conducting successful trials that meet regulatory standards and achieve operational excellence.  nnThe article emphasizes several key factors that contribute to successful site selection. First, a thorough understanding of Brazil's regulatory landscape, including compliance with ANVISA and ICH-GCP standards, is crucial. Second, the importance of defining selection criteria, conducting feasibility studies, and leveraging local networks cannot be overstated. Finally, establishing strong communication and collaboration with site personnel ensures that all stakeholders are aligned and can navigate challenges effectively.  nnAs Brazil's prominence as a hub for clinical trials grows, how can stakeholders adopt a strategic approach to site selection? By prioritizing regulatory compliance, logistical efficiency, and effective patient recruitment strategies, researchers can capitalize on Brazil's unique advantages for early-stage clinical trials. This proactive approach will not only streamline the trial process but also contribute to the timely introduction of innovative therapies to the market, ultimately benefiting both patients and the broader healthcare landscape.nn::iframe[https://iframe.tely.ai/cta/eyJhcnRpY2xlX2lkIjogIjY5ZjNlZDFhOTJiYTZiMzkyM2RhOGQ3OCIsICJjb21wYW55X2lkIjogIjY2OTk4NmYwMzM1YWQwNDI3ZTVmNTdlMyIsICJpbmRleCI6IG51bGwsICJ0eXBlIjogImFydGljbGUifQ==]{width="100%" height="300px"}", "image": ["https://images.tely.ai/telyai/rtsjkopf-this-flowchart-guides-you-through-the-essential-steps-for-navigating-the-regulatory-landscape-for-clinical-trials-in-brazil-each-box-represents-a-key-component-of-the-process-and-the-arrows-show-how-they-connect-and-flow-into-one-another.webp", "https://images.tely.ai/telyai/wgxvvhad-this-flowchart-outlines-the-steps-to-identify-and-evaluate-clinical-trial-sites-each-box-represents-a-key-step-in-the-process-and-the-arrows-show-the-order-in-which-to-follow-them-start-at-the-top-and-move-down-to-ensure-you-cover-all-necessary-aspects-for-successful-site-selection.webp", "https://images.tely.ai/telyai/zskpovqz-this-mindmap-starts-with-the-main-topic-in-the-center-and-branches-out-into-key-areas-to-consider-for-successful-clinical-trials-each-branch-represents-a-different-aspect-of-logistics-and-recruitment-with-further-details-provided-in-the-sub-branches-follow-the-connections-to-see-how-each-factor-contributes-to-the-overall-strategy.webp", "https://images.tely.ai/telyai/gjciscev-this-flowchart-outlines-the-steps-to-improve-communication-and-collaboration-at-a-clinical-trial-site-each-box-represents-a-key-practice-and-the-arrows-show-how-these-practices-connect-to-create-a-successful-communication-strategy.webp"], "inLanguage": "en", "author": {"@type": "Organization", "name": "bioaccess®"}, "publisher": {"@type": "Organization", "name": "bioaccess®", "url": "https://bioaccessla.com"}}</script>

  • Navigate Ethics Committee Approval For Clinical Trials In Brazil

    <h2 id="introduction">Introduction</h2>

    <p>Understanding the pivotal role of ethics committees is essential for successfully navigating clinical trials in Brazil. This guide outlines the essential steps for obtaining ethics committee approval and highlights recent legislative changes that enhance trial initiation efficiency.</p>

    <p>However, researchers often face significant challenges, including:</p>

    <ul>

    <li>Lengthy approval timelines</li>

    <li>Complex documentation requirements</li>

    </ul>

    <p>What strategies can sponsors employ to overcome these hurdles and ensure their clinical studies launch on time? These challenges can lead to delays that jeopardize the entire research timeline. Addressing these challenges head-on is crucial for ensuring timely and successful clinical study launches.</p>

    <h2 id="understand-the-role-of-ethics-committees-in-clinical-trials">Understand the Role of Ethics Committees in Clinical Trials</h2>

    <p>Navigating the complexities of clinical research in Brazil hinges on understanding the pivotal role of <a href="https://bioaccessla.com/news/axoft-receives-ethics-committee-approval-for-first-in-human-clinical-trial-in-panama">ethics committee approval</a> for conducting a <a href="https://bioaccessla.com/br/contact-us">clinical trial</a>, which is essential for safeguarding participant welfare and ensuring compliance with ethical standards. Let’s explore their key functions:</p>

    <ol>

    <li>Protocol Review: Ethics committees meticulously evaluate research protocols to confirm that study designs are ethical and that risks to participants are minimized. This assessment is essential for ensuring participant safety and confirming that the study is scientifically sound.</li>

    <li>Informed Consent: They assess <a href="https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety" rel="noopener noreferrer nofollow" target="_blank">informed consent documents</a> to guarantee that participants are fully informed about the study, including potential risks and benefits. This process is vital for upholding the autonomy and rights of participants.</li>

    <li>Continuous Oversight: Throughout the study, review boards provide ongoing supervision to ensure adherence to standards and to address any adverse events that may occur. This ongoing monitoring is essential for maintaining the integrity of the research.</li>

    <li><a href="https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety" rel="noopener noreferrer nofollow" target="_blank">Authorization Process</a>: Before a clinical study can begin, it must obtain ethics committee approval for the Brazil clinical trial, which is a prerequisite for submission to ANVISA (Agência Nacional de Vigilância Sanitária). The ethical review must be finalized within 30 business days from the acceptance of all research documents, significantly affecting the overall timeline for study initiation. If additional information is required, delays in the authorization process can hinder timely study initiation, impacting research outcomes.</li>

    </ol>

    <p>Comprehending these roles is essential for navigating the authorization process efficiently, especially for <a href="https://bioaccessla.com/br/services">first-in-human studies</a> where ethical concerns are critical. With the <a href="https://psi-cro.com/brazil-new-clinical-research-law" rel="noopener noreferrer nofollow" target="_blank">new law</a>, researchers can expect a more streamlined authorization process, allowing for quicker study launches. As the landscape evolves with new regulations, staying informed about these changes will be crucial for researchers aiming to expedite their studies while upholding ethical integrity.</p>

    <p><img alt="This mindmap illustrates the essential roles of ethics committees in clinical trials. Start at the center with the main role, then follow the branches to see each specific function and its importance in ensuring ethical standards and participant safety." src="https://images.tely.ai/telyai/eyvmppxa-this-mindmap-illustrates-the-essential-roles-of-ethics-committees-in-clinical-trials-start-at-the-center-with-the-main-role-then-follow-the-branches-to-see-each-specific-function-and-its-importance-in-ensuring-ethical-standards-and-participant-safety.webp" title="This mindmap illustrates the essential roles of ethics committees in clinical trials. Start at the center with the main role, then follow the branches to see each specific function and its importance in ensuring ethical standards and participant safety."/></p>

    <h2 id="review-brazils-regulatory-framework-for-ethics-approval">Review Brazil's Regulatory Framework for Ethics Approval</h2>

    <p>Navigating Brazil's evolving regulatory landscape for clinical research sponsors involves obtaining <a href="https://bioaccessla.com/es/services">ethics committee approval for clinical trials</a>, presenting both challenges and opportunities. The regulatory framework for studies is primarily overseen by ANVISA and the <a href="https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil" rel="noopener noreferrer nofollow" target="_blank">newly formed National Ethics Committee (INAEP)</a>, which is essential for obtaining ethics committee approval for <a href="https://bioaccessla.com/latin-america-medtech-research-site-search-and-selection">Brazil clinical trials</a>. Here are the key components of this framework:</p>

    <ol>

    <li>ANVISA Submission: All <a href="https://bioaccessla.com/services">clinical trials must be submitted to ANVISA</a> for evaluation. The review process is limited to 90 business days, greatly improving the pace of authorizations compared to prior timelines.</li>

    <li>Under INAEP Oversight, researchers must now secure <a href="https://bioaccessla.com/blog/5-key-practices-for-patient-safety-under-cofepris-regulations">ethics committee approval in Brazil</a> for the clinical trial before submitting to ANVISA. This ensures that <a href="https://bioaccessla.com/blog/4-best-practices-for-fda-guidance-validation-in-clinical-research">ethical standards are upheld</a> throughout the research process, including the requirement for ethics committee approval for the Brazil clinical trial, with INAEP supervising local committees to maintain consistency.</li>

    <li><a href="https://bioaccessla.com/blog/10-serbian-sop-templates-for-streamlined-trial-compliance">Plataforma Brasil</a>: Researchers must register their studies on Plataforma Brasil, the national system for ethical clearance. This platform simplifies the submission process and enables tracking of endorsements, enhancing communication among stakeholders.</li>

    <li>New Regulations: As of May 2024, Brazil enacted <a href="https://clinicalleader.com/doc/how-brazil-s-new-law-is-redefining-the-country-s-clinical-research-0001" rel="noopener noreferrer nofollow" target="_blank">Law No. 14.874</a>, which streamlines the process by permitting simultaneous submissions to ANVISA and review boards. This regulatory flexibility is anticipated to encourage innovation and enhance Brazil's competitiveness in the global research landscape.</li>

    </ol>

    <p>Understanding this regulatory framework is crucial for sponsors who want to effectively navigate the complexities of ethical consent and obtain ethics committee approval for a clinical trial in Brazil. These changes position Brazil as a more attractive destination for innovative clinical research, fostering growth in the Medtech sector.</p>

    <p><img alt="This flowchart outlines the steps needed to obtain ethics committee approval for clinical trials in Brazil. Each box represents a key step in the process, and the arrows show the order in which these steps should be completed. Follow the flow to understand how to navigate the regulatory landscape effectively." src="https://images.tely.ai/telyai/dwholqnu-this-flowchart-outlines-the-steps-needed-to-obtain-ethics-committee-approval-for-clinical-trials-in-brazil-each-box-represents-a-key-step-in-the-process-and-the-arrows-show-the-order-in-which-these-steps-should-be-completed-follow-the-flow-to-understand-how-to-navigate-the-regulatory-landscape-effectively.webp" title="This flowchart outlines the steps needed to obtain ethics committee approval for clinical trials in Brazil. Each box represents a key step in the process, and the arrows show the order in which these steps should be completed. Follow the flow to understand how to navigate the regulatory landscape effectively."/></p>

    <h2 id="prepare-and-submit-required-documentation-for-approval">Prepare and Submit Required Documentation for Approval</h2>

    <p>Gaining <a href="https://bioaccessla.com/market-access">ethics committee approval</a> for a clinical trial in Brazil is a critical yet intricate process that demands meticulous attention to detail. To navigate this landscape effectively, sponsors must prepare and submit a comprehensive set of documents. Here’s a step-by-step guide:</p>

    <ol>

    <li>

    <p>Compile <a href="https://bioaccessla.com/blog/10-essential-edc-software-features-for-clinical-research-directors">Essential Documents</a>: The following documents are typically required:</p>

    <ul>

    <li>Research protocol</li>

    <li>Informed consent forms</li>

    <li>Investigator's brochure</li>

    <li>Case report forms (CRFs)</li>

    <li>Ethics committee approval from the local CEP</li>

    <li>Any previous approvals or correspondence with <a href="https://bioaccessla.com/resources">regulatory bodies</a></li>

    </ul>

    </li>

    <li>

    <p>Register on <a href="https://bioaccessla.com/blog/10-key-regulatory-considerations-for-rare-disease-trials-in-romania">Plataforma Brasil</a>: Create an account on Plataforma Brasil, the national registry for clinical research, and register your study. Ensure that all required documents are uploaded in the correct format, including electronic copies with text searching capability.</p>

    </li>

    <li>

    <p>Submit to Local CEP: Once registered, submit your application to the <a href="https://bioaccessla.com/blog/10-steps-for-effective-ec-ce-compliance-in-medical-devices">local committee</a> for review. This submission must include all necessary documentation and a cover letter outlining the study's objectives and significance. The CEP will review the protocol documentation for completeness within 10 days of submission and issue an initial report within 30 days after full acceptance of the protocol documents.</p>

    </li>

    <li>

    <p>Follow Up: After submission, staying in touch with the review board can really help make the review process smoother. Address any questions or requests for additional information promptly to facilitate a more efficient review.</p>

    </li>

    <li>

    <p>Prepare for <a href="https://globalregulatorypartners.com/clinical-trials-for-drugs-medicines-in-brazil-and-the-clinical-trial-application-process" rel="noopener noreferrer nofollow" target="_blank">ANVISA Submission</a>: Once you obtain consent from the local CEP, prepare your submission for ANVISA. You need to ensure that all documents meet their criteria. This includes proof of the ethics committee approval for the Brazil clinical trial and a detailed research protocol. ANVISA generally requires 90 calendar days to assess the application, and if no feedback is provided within this period, development can proceed, assuming ethical permissions are in place.</p>

    </li>

    </ol>

    <p>Ultimately, a well-prepared submission can significantly streamline the path to successful <a href="https://bioaccessla.com/br/about">clinical trials in Brazil</a>.</p>

    <p><img alt="This flowchart shows the steps you need to take to get approval for a clinical trial in Brazil. Start at the top and follow the arrows down to see what you need to do at each stage, including what documents to prepare and where to submit them." src="https://images.tely.ai/telyai/lmoybooh-this-flowchart-shows-the-steps-you-need-to-take-to-get-approval-for-a-clinical-trial-in-brazil-start-at-the-top-and-follow-the-arrows-down-to-see-what-you-need-to-do-at-each-stage-including-what-documents-to-prepare-and-where-to-submit-them.webp" title="This flowchart shows the steps you need to take to get approval for a clinical trial in Brazil. Start at the top and follow the arrows down to see what you need to do at each stage, including what documents to prepare and where to submit them."/></p>

    <h2 id="identify-and-overcome-common-challenges-in-the-approval-process">Identify and Overcome Common Challenges in the Approval Process</h2>

    <p>Navigating the review process for research in Brazil can present several challenges that may impede <a href="https://bioaccessla.com/br/news">timely progress</a>. Here are some common obstacles and strategies to overcome them:</p>

    <ol>

    <li><a href="https://bioaccessla.com/blog/10-essential-steps-of-randomised-control-trial-for-clinical-success">Lengthy Approval Times</a>: Authorization from review boards can take longer than anticipated, often surpassing 180 days under the previous system. Recent <a href="https://bioaccessla.com/solutions">regulatory changes</a> now allow for a maximum approval time of just 30 days for standard submissions, and even less for strategic research. To mitigate delays, submit your application well in advance and ensure that all documentation is complete and accurate.</li>

    <li><a href="https://bioaccessla.com/blog/10-croatia-ethics-committee-so-ps-every-sponsor-must-know">Incomplete Documentation</a>: One of the most common reasons for delays is incomplete submissions. Statistics show that incomplete documentation is a significant factor in delays of authorization. Make sure to use a comprehensive checklist to confirm that all required documents, including Informed Consent Forms (ICFs) and study protocols, are included before submission.</li>

    <li><a href="https://bioaccessla.com/blog/7-strategies-to-enhance-diversity-in-clinical-trials">Communication Gaps</a>: Maintain open lines of communication with the compliance committee. Regularly follow up on the status of your application and be responsive to any requests for additional information. This proactive approach can help clarify any uncertainties and expedite the review process.</li>

    <li>Regulatory Changes: Stay informed about changes in regulations, such as the recent enactment of <a href="https://ibanet.org/Brazil-enacts-new-law-to-regulate-clinical-trials" rel="noopener noreferrer nofollow" target="_blank">Law No. 14,874/2024 and Executive Order #12,651/2025</a>, which simplify the process for obtaining consent. Subscribe to updates from ANVISA and the National Research Ethics Board (INEP) to remain compliant and aware of any new requirements.</li>

    <li>Cultural Differences: Grasping the local context and cultural subtleties can enable smoother interactions with review committees. Engaging local experts or consultants who are familiar with the Brazilian regulatory landscape can provide valuable insights and enhance communication.</li>

    </ol>

    <p>Addressing these challenges not only streamlines the approval process but also positions sponsors for success in bringing innovative therapies to market.</p>

    <p><img alt="Each box represents a challenge faced during the approval process, and the arrows lead to strategies that can help overcome these challenges. Follow the flow to see how to tackle each obstacle effectively." src="https://images.tely.ai/telyai/ijcsaudr-each-box-represents-a-challenge-faced-during-the-approval-process-and-the-arrows-lead-to-strategies-that-can-help-overcome-these-challenges-follow-the-flow-to-see-how-to-tackle-each-obstacle-effectively.webp" title="Each box represents a challenge faced during the approval process, and the arrows lead to strategies that can help overcome these challenges. Follow the flow to see how to tackle each obstacle effectively."/></p>

    <h2 id="conclusion">Conclusion</h2>

    <p>The ethics committee approval process in Brazil presents both challenges and opportunities for clinical trial researchers. Researchers must grasp the vital roles of ethics committees, which range from reviewing protocols to providing ongoing oversight. The recent regulatory changes have streamlined this process, offering a clearer path for obtaining necessary approvals.</p>

    <p>This article highlights key components of Brazil's regulatory framework, including the importance of ANVISA submissions and the need for registering on Plataforma Brasil. Navigating the registration process on Plataforma Brasil can be daunting for many researchers. Additionally, the new law facilitates simultaneous submissions, simplifying the process and accelerating the timeline for research initiatives. Comprehensive documentation and proactive communication with ethics committees are essential to overcoming common challenges, such as lengthy approval times and incomplete submissions.</p>

    <p>Ultimately, the significance of ethics committee approval extends beyond compliance; it fosters a culture of safety and respect for participants in clinical trials. By understanding and addressing the challenges outlined, researchers can enhance their chances of success in bringing innovative therapies to market. Engaging with local experts and staying informed about regulatory changes will not only expedite the approval process but also position Brazil as a competitive player in the global clinical research landscape. By mastering these processes, researchers can not only ensure compliance but also contribute to the advancement of medical science in Brazil.</p>

    <p><iframe frameborder="0" height="300px" loading="lazy" src="https://iframe.tely.ai/cta/eyJhcnRpY2xlX2lkIjogIjY5ZjUzZWY4ODdhNmQ3Y2IxOTU5MjYyZCIsICJjb21wYW55X2lkIjogIjY2OTk4NmYwMzM1YWQwNDI3ZTVmNTdlMyIsICJpbmRleCI6IG51bGwsICJ0eXBlIjogImFydGljbGUifQ==" width="100%"></iframe></p>

    <h2 id="frequently-asked-questions">Frequently Asked Questions</h2>

    <p><strong>What is the role of ethics committees in clinical trials in Brazil?</strong></p>

    <p>Ethics committees play a crucial role in clinical trials in Brazil by reviewing research protocols to ensure they are ethical, assessing informed consent documents to protect participant rights, providing continuous oversight during the study, and approving studies before they can begin.</p>

    <p><strong>How do ethics committees evaluate research protocols?</strong></p>

    <p>Ethics committees meticulously evaluate research protocols to confirm that study designs are ethical and that risks to participants are minimized, ensuring participant safety and scientific soundness.</p>

    <p><strong>What is the importance of informed consent in clinical trials?</strong></p>

    <p>Informed consent is vital as ethics committees assess the consent documents to ensure participants are fully informed about the study, including potential risks and benefits, thereby upholding their autonomy and rights.</p>

    <p><strong>What kind of oversight do ethics committees provide during a clinical study?</strong></p>

    <p>Ethics committees provide ongoing supervision throughout the study to ensure adherence to ethical standards and to address any adverse events that may occur, maintaining the integrity of the research.</p>

    <p><strong>What is the authorization process for a clinical study in Brazil?</strong></p>

    <p>Before a clinical study can commence, it must obtain ethics committee approval, which is a prerequisite for submission to ANVISA. The ethical review must be finalized within 30 business days from the acceptance of all research documents.</p>

    <p><strong>How can delays in the authorization process impact clinical trials?</strong></p>

    <p>If additional information is required during the ethics committee review, it can delay the authorization process, hindering timely study initiation and potentially impacting research outcomes.</p>

    <p><strong>What recent changes have been made to the authorization process for clinical trials?</strong></p>

    <p>Recent changes in the law have led to a more streamlined authorization process, allowing for quicker study launches, which is particularly beneficial for first-in-human studies where ethical concerns are critical.</p>

    <p><strong>Why is it important for researchers to stay informed about changes in regulations?</strong></p>

    <p>Staying informed about evolving regulations is crucial for researchers aiming to expedite their studies while maintaining ethical integrity, especially in the context of first-in-human and early feasibility clinical trials.</p>

    <h2 id="list-of-sources">List of Sources</h2>

    <ol>

    <li>Understand the Role of Ethics Committees in Clinical Trials

    <ul>

    <li>What to Know About Brazil’s New Clinical Research Law (https://psi-cro.com/brazil-new-clinical-research-law)</li>

    <li>Avaliação de ensaios clínicos no Brasil: histórico e atualidades (https://scielo.br/j/bioet/a/Bhk4bDL8wYTZtPc6PrpWycQ?format=pdf&amp;lang=en)</li>

    <li>The Role of Ethics Committees in Clinical Trials – TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO (https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety)</li>

    <li>7 essential roles of ethics committee in clinical trials (https://pharmaeducenter.com/blog/role-of-ethics-committee-in-clinical-trials)</li>

    </ul>

    </li>

    <li>Review Brazil's Regulatory Framework for Ethics Approval

    <ul>

    <li>Brazil Just Changed The Rules For Clinical Trial Approvals — What Sponsors Need To Know | bioaccess® (https://bioaccessla.com/blog/brazil-anvisa-parallel-review-clinical-trial-approvals-2026)</li>

    <li>New regulations for clinical research in Brazil | Licks Attorneys (https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil)</li>

    <li>Brazil Cuts Clinical Trial Approval Timeline to 90 Days | bioaccess®: Fast-Tracking First-in-Human Trials, Anywhere posted on the topic | LinkedIn (https://linkedin.com/posts/bioaccess_clinicaltrials-brazil-anvisa-activity-7447976698958106627-98MW)</li>

    <li>How Brazil's New Law Is Redefining The Country's Clinical Research (https://clinicalleader.com/doc/how-brazil-s-new-law-is-redefining-the-country-s-clinical-research-0001)</li>

    </ul>

    </li>

    <li>Prepare and Submit Required Documentation for Approval

    <ul>

    <li>Clinical Trial Regulatory Process – Brazil | Credevo Articles (https://credevo.com/articles/2019/03/14/clinical-trial-regulatory-process-brazil)</li>

    <li>Clinical Trials for Drugs/Medicines in Brazil and the Clinical Trial Application process (https://globalregulatorypartners.com/clinical-trials-for-drugs-medicines-in-brazil-and-the-clinical-trial-application-process)</li>

    </ul>

    </li>

    <li>Identify and Overcome Common Challenges in the Approval Process

    <ul>

    <li>New regulations for clinical research in Brazil | Licks Attorneys (https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil)</li>

    <li>Brazil enacts a law to regulate clinical trials (https://ibanet.org/Brazil-enacts-new-law-to-regulate-clinical-trials)</li>

    <li>Best Practices For First-In-Human Clinical Trials In Brazil | bioaccess® (https://bioaccessla.com/blog/best-practices-for-first-in-human-clinical-trials-in-brazil)</li>

    <li>Understanding Ethics Committee Considerations … | bioaccess® (https://bioaccessla.com/blog/understanding-ethics-committee-considerations-in-brazil-a-comprehensive-tutorial)</li>

    </ul>

    </li>

    </ol>

    <script type="application/ld+json">{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "What is the role of ethics committees in clinical trials in Brazil?", "acceptedAnswer": {"@type": "Answer", "text": "Ethics committees play a crucial role in clinical trials in Brazil by reviewing research protocols to ensure they are ethical, assessing informed consent documents to protect participant rights, providing continuous oversight during the study, and approving studies before they can begin."}}, {"@type": "Question", "name": "How do ethics committees evaluate research protocols?", "acceptedAnswer": {"@type": "Answer", "text": "Ethics committees meticulously evaluate research protocols to confirm that study designs are ethical and that risks to participants are minimized, ensuring participant safety and scientific soundness."}}, {"@type": "Question", "name": "What is the importance of informed consent in clinical trials?", "acceptedAnswer": {"@type": "Answer", "text": "Informed consent is vital as ethics committees assess the consent documents to ensure participants are fully informed about the study, including potential risks and benefits, thereby upholding their autonomy and rights."}}, {"@type": "Question", "name": "What kind of oversight do ethics committees provide during a clinical study?", "acceptedAnswer": {"@type": "Answer", "text": "Ethics committees provide ongoing supervision throughout the study to ensure adherence to ethical standards and to address any adverse events that may occur, maintaining the integrity of the research."}}, {"@type": "Question", "name": "What is the authorization process for a clinical study in Brazil?", "acceptedAnswer": {"@type": "Answer", "text": "Before a clinical study can commence, it must obtain ethics committee approval, which is a prerequisite for submission to ANVISA. The ethical review must be finalized within 30 business days from the acceptance of all research documents."}}, {"@type": "Question", "name": "How can delays in the authorization process impact clinical trials?", "acceptedAnswer": {"@type": "Answer", "text": "If additional information is required during the ethics committee review, it can delay the authorization process, hindering timely study initiation and potentially impacting research outcomes."}}, {"@type": "Question", "name": "What recent changes have been made to the authorization process for clinical trials?", "acceptedAnswer": {"@type": "Answer", "text": "Recent changes in the law have led to a more streamlined authorization process, allowing for quicker study launches, which is particularly beneficial for first-in-human studies where ethical concerns are critical."}}, {"@type": "Question", "name": "Why is it important for researchers to stay informed about changes in regulations?", "acceptedAnswer": {"@type": "Answer", "text": "Staying informed about evolving regulations is crucial for researchers aiming to expedite their studies while maintaining ethical integrity, especially in the context of first-in-human and early feasibility clinical trials."}}]}</script><script type="application/ld+json">{"@context": "https://schema.org", "@type": "BlogPosting", "headline": "Navigate Ethics Committee Approval for Clinical Trials in Brazil", "description": "Navigate the ethics committee approval process for clinical trials in Brazil efficiently and successfully.", "datePublished": "2026-05-02T00:02:00.602000", "dateModified": "2026-05-02T04:47:39.578139+00:00", "articleBody": "## IntroductionnUnderstanding the pivotal role of ethics committees is essential for successfully navigating clinical trials in Brazil. This guide outlines the essential steps for obtaining ethics committee approval and highlights recent legislative changes that enhance trial initiation efficiency. nnHowever, researchers often face significant challenges, including:nn- Lengthy approval timelinesn- Complex documentation requirementsnnWhat strategies can sponsors employ to overcome these hurdles and ensure their clinical studies launch on time? These challenges can lead to delays that jeopardize the entire research timeline. Addressing these challenges head-on is crucial for ensuring timely and successful clinical study launches.nn## Understand the Role of Ethics Committees in Clinical TrialsnnNavigating the complexities of clinical research in Brazil hinges on understanding the pivotal role of [ethics committee approval](https://bioaccessla.com/news/axoft-receives-ethics-committee-approval-for-first-in-human-clinical-trial-in-panama) for conducting a [clinical trial](https://bioaccessla.com/br/contact-us), which is essential for safeguarding participant welfare and ensuring compliance with ethical standards. Let’s explore their key functions:nn1. Protocol Review: Ethics committees meticulously evaluate research protocols to confirm that study designs are ethical and that risks to participants are minimized. This assessment is essential for ensuring participant safety and confirming that the study is scientifically sound.n2. Informed Consent: They assess [informed consent documents](https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety) to guarantee that participants are fully informed about the study, including potential risks and benefits. This process is vital for upholding the autonomy and rights of participants.n3. Continuous Oversight: Throughout the study, review boards provide ongoing supervision to ensure adherence to standards and to address any adverse events that may occur. This ongoing monitoring is essential for maintaining the integrity of the research.n4. [Authorization Process](https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety): Before a clinical study can begin, it must obtain ethics committee approval for the Brazil clinical trial, which is a prerequisite for submission to ANVISA (Agência Nacional de Vigilância Sanitária). The ethical review must be finalized within 30 business days from the acceptance of all research documents, significantly affecting the overall timeline for study initiation. If additional information is required, delays in the authorization process can hinder timely study initiation, impacting research outcomes.nnComprehending these roles is essential for navigating the authorization process efficiently, especially for [first-in-human studies](https://bioaccessla.com/br/services) where ethical concerns are critical. With the [new law](https://psi-cro.com/brazil-new-clinical-research-law), researchers can expect a more streamlined authorization process, allowing for quicker study launches. As the landscape evolves with new regulations, staying informed about these changes will be crucial for researchers aiming to expedite their studies while upholding ethical integrity.nn![This mindmap illustrates the essential roles of ethics committees in clinical trials. Start at the center with the main role, then follow the branches to see each specific function and its importance in ensuring ethical standards and participant safety.](https://images.tely.ai/telyai/eyvmppxa-this-mindmap-illustrates-the-essential-roles-of-ethics-committees-in-clinical-trials-start-at-the-center-with-the-main-role-then-follow-the-branches-to-see-each-specific-function-and-its-importance-in-ensuring-ethical-standards-and-participant-safety.webp "This mindmap illustrates the essential roles of ethics committees in clinical trials. Start at the center with the main role, then follow the branches to see each specific function and its importance in ensuring ethical standards and participant safety.")nn## Review Brazil's Regulatory Framework for Ethics ApprovalnnNavigating Brazil's evolving regulatory landscape for clinical research sponsors involves obtaining [ethics committee approval for clinical trials](https://bioaccessla.com/es/services), presenting both challenges and opportunities. The regulatory framework for studies is primarily overseen by ANVISA and the [newly formed National Ethics Committee (INAEP)](https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil), which is essential for obtaining ethics committee approval for [Brazil clinical trials](https://bioaccessla.com/latin-america-medtech-research-site-search-and-selection). Here are the key components of this framework:nn1. ANVISA Submission: All [clinical trials must be submitted to ANVISA](https://bioaccessla.com/services) for evaluation. The review process is limited to 90 business days, greatly improving the pace of authorizations compared to prior timelines.n2. Under INAEP Oversight, researchers must now secure [ethics committee approval in Brazil](https://bioaccessla.com/blog/5-key-practices-for-patient-safety-under-cofepris-regulations) for the clinical trial before submitting to ANVISA. This ensures that [ethical standards are upheld](https://bioaccessla.com/blog/4-best-practices-for-fda-guidance-validation-in-clinical-research) throughout the research process, including the requirement for ethics committee approval for the Brazil clinical trial, with INAEP supervising local committees to maintain consistency.n3. [Plataforma Brasil](https://bioaccessla.com/blog/10-serbian-sop-templates-for-streamlined-trial-compliance): Researchers must register their studies on Plataforma Brasil, the national system for ethical clearance. This platform simplifies the submission process and enables tracking of endorsements, enhancing communication among stakeholders.n4. New Regulations: As of May 2024, Brazil enacted [Law No. 14.874](https://clinicalleader.com/doc/how-brazil-s-new-law-is-redefining-the-country-s-clinical-research-0001), which streamlines the process by permitting simultaneous submissions to ANVISA and review boards. This regulatory flexibility is anticipated to encourage innovation and enhance Brazil's competitiveness in the global research landscape.nnUnderstanding this regulatory framework is crucial for sponsors who want to effectively navigate the complexities of ethical consent and obtain ethics committee approval for a clinical trial in Brazil. These changes position Brazil as a more attractive destination for innovative clinical research, fostering growth in the Medtech sector.nn![This flowchart outlines the steps needed to obtain ethics committee approval for clinical trials in Brazil. Each box represents a key step in the process, and the arrows show the order in which these steps should be completed. Follow the flow to understand how to navigate the regulatory landscape effectively.](https://images.tely.ai/telyai/dwholqnu-this-flowchart-outlines-the-steps-needed-to-obtain-ethics-committee-approval-for-clinical-trials-in-brazil-each-box-represents-a-key-step-in-the-process-and-the-arrows-show-the-order-in-which-these-steps-should-be-completed-follow-the-flow-to-understand-how-to-navigate-the-regulatory-landscape-effectively.webp "This flowchart outlines the steps needed to obtain ethics committee approval for clinical trials in Brazil. Each box represents a key step in the process, and the arrows show the order in which these steps should be completed. Follow the flow to understand how to navigate the regulatory landscape effectively.")nn## Prepare and Submit Required Documentation for ApprovalnnGaining [ethics committee approval](https://bioaccessla.com/market-access) for a clinical trial in Brazil is a critical yet intricate process that demands meticulous attention to detail. To navigate this landscape effectively, sponsors must prepare and submit a comprehensive set of documents. Here’s a step-by-step guide:nn1. Compile [Essential Documents](https://bioaccessla.com/blog/10-essential-edc-software-features-for-clinical-research-directors): The following documents are typically required:nn   – Research protocoln   – Informed consent formsn   – Investigator's brochuren   – Case report forms (CRFs)n   – Ethics committee approval from the local CEPn   – Any previous approvals or correspondence with [regulatory bodies](https://bioaccessla.com/resources)n2. Register on [Plataforma Brasil](https://bioaccessla.com/blog/10-key-regulatory-considerations-for-rare-disease-trials-in-romania): Create an account on Plataforma Brasil, the national registry for clinical research, and register your study. Ensure that all required documents are uploaded in the correct format, including electronic copies with text searching capability.n3. Submit to Local CEP: Once registered, submit your application to the [local committee](https://bioaccessla.com/blog/10-steps-for-effective-ec-ce-compliance-in-medical-devices) for review. This submission must include all necessary documentation and a cover letter outlining the study's objectives and significance. The CEP will review the protocol documentation for completeness within 10 days of submission and issue an initial report within 30 days after full acceptance of the protocol documents.n4. Follow Up: After submission, staying in touch with the review board can really help make the review process smoother. Address any questions or requests for additional information promptly to facilitate a more efficient review.n5. Prepare for [ANVISA Submission](https://globalregulatorypartners.com/clinical-trials-for-drugs-medicines-in-brazil-and-the-clinical-trial-application-process): Once you obtain consent from the local CEP, prepare your submission for ANVISA. You need to ensure that all documents meet their criteria. This includes proof of the ethics committee approval for the Brazil clinical trial and a detailed research protocol. ANVISA generally requires 90 calendar days to assess the application, and if no feedback is provided within this period, development can proceed, assuming ethical permissions are in place.nnUltimately, a well-prepared submission can significantly streamline the path to successful [clinical trials in Brazil](https://bioaccessla.com/br/about).nn![This flowchart shows the steps you need to take to get approval for a clinical trial in Brazil. Start at the top and follow the arrows down to see what you need to do at each stage, including what documents to prepare and where to submit them.](https://images.tely.ai/telyai/lmoybooh-this-flowchart-shows-the-steps-you-need-to-take-to-get-approval-for-a-clinical-trial-in-brazil-start-at-the-top-and-follow-the-arrows-down-to-see-what-you-need-to-do-at-each-stage-including-what-documents-to-prepare-and-where-to-submit-them.webp "This flowchart shows the steps you need to take to get approval for a clinical trial in Brazil. Start at the top and follow the arrows down to see what you need to do at each stage, including what documents to prepare and where to submit them.")nn## Identify and Overcome Common Challenges in the Approval ProcessnnNavigating the review process for research in Brazil can present several challenges that may impede [timely progress](https://bioaccessla.com/br/news). Here are some common obstacles and strategies to overcome them:nn1. [Lengthy Approval Times](https://bioaccessla.com/blog/10-essential-steps-of-randomised-control-trial-for-clinical-success): Authorization from review boards can take longer than anticipated, often surpassing 180 days under the previous system. Recent [regulatory changes](https://bioaccessla.com/solutions) now allow for a maximum approval time of just 30 days for standard submissions, and even less for strategic research. To mitigate delays, submit your application well in advance and ensure that all documentation is complete and accurate.n2. [Incomplete Documentation](https://bioaccessla.com/blog/10-croatia-ethics-committee-so-ps-every-sponsor-must-know): One of the most common reasons for delays is incomplete submissions. Statistics show that incomplete documentation is a significant factor in delays of authorization. Make sure to use a comprehensive checklist to confirm that all required documents, including Informed Consent Forms (ICFs) and study protocols, are included before submission.n3. [Communication Gaps](https://bioaccessla.com/blog/7-strategies-to-enhance-diversity-in-clinical-trials): Maintain open lines of communication with the compliance committee. Regularly follow up on the status of your application and be responsive to any requests for additional information. This proactive approach can help clarify any uncertainties and expedite the review process.n4. Regulatory Changes: Stay informed about changes in regulations, such as the recent enactment of [Law No. 14,874/2024 and Executive Order #12,651/2025](https://ibanet.org/Brazil-enacts-new-law-to-regulate-clinical-trials), which simplify the process for obtaining consent. Subscribe to updates from ANVISA and the National Research Ethics Board (INEP) to remain compliant and aware of any new requirements.n5. Cultural Differences: Grasping the local context and cultural subtleties can enable smoother interactions with review committees. Engaging local experts or consultants who are familiar with the Brazilian regulatory landscape can provide valuable insights and enhance communication.nnAddressing these challenges not only streamlines the approval process but also positions sponsors for success in bringing innovative therapies to market.nn![Each box represents a challenge faced during the approval process, and the arrows lead to strategies that can help overcome these challenges. Follow the flow to see how to tackle each obstacle effectively.](https://images.tely.ai/telyai/ijcsaudr-each-box-represents-a-challenge-faced-during-the-approval-process-and-the-arrows-lead-to-strategies-that-can-help-overcome-these-challenges-follow-the-flow-to-see-how-to-tackle-each-obstacle-effectively.webp "Each box represents a challenge faced during the approval process, and the arrows lead to strategies that can help overcome these challenges. Follow the flow to see how to tackle each obstacle effectively.")nn## ConclusionnThe ethics committee approval process in Brazil presents both challenges and opportunities for clinical trial researchers. Researchers must grasp the vital roles of ethics committees, which range from reviewing protocols to providing ongoing oversight. The recent regulatory changes have streamlined this process, offering a clearer path for obtaining necessary approvals.  nnThis article highlights key components of Brazil's regulatory framework, including the importance of ANVISA submissions and the need for registering on Plataforma Brasil. Navigating the registration process on Plataforma Brasil can be daunting for many researchers. Additionally, the new law facilitates simultaneous submissions, simplifying the process and accelerating the timeline for research initiatives. Comprehensive documentation and proactive communication with ethics committees are essential to overcoming common challenges, such as lengthy approval times and incomplete submissions.  nnUltimately, the significance of ethics committee approval extends beyond compliance; it fosters a culture of safety and respect for participants in clinical trials. By understanding and addressing the challenges outlined, researchers can enhance their chances of success in bringing innovative therapies to market. Engaging with local experts and staying informed about regulatory changes will not only expedite the approval process but also position Brazil as a competitive player in the global clinical research landscape. By mastering these processes, researchers can not only ensure compliance but also contribute to the advancement of medical science in Brazil.nn::iframe[https://iframe.tely.ai/cta/eyJhcnRpY2xlX2lkIjogIjY5ZjUzZWY4ODdhNmQ3Y2IxOTU5MjYyZCIsICJjb21wYW55X2lkIjogIjY2OTk4NmYwMzM1YWQwNDI3ZTVmNTdlMyIsICJpbmRleCI6IG51bGwsICJ0eXBlIjogImFydGljbGUifQ==]{width="100%" height="300px"}", "image": ["https://images.tely.ai/telyai/eyvmppxa-this-mindmap-illustrates-the-essential-roles-of-ethics-committees-in-clinical-trials-start-at-the-center-with-the-main-role-then-follow-the-branches-to-see-each-specific-function-and-its-importance-in-ensuring-ethical-standards-and-participant-safety.webp", "https://images.tely.ai/telyai/dwholqnu-this-flowchart-outlines-the-steps-needed-to-obtain-ethics-committee-approval-for-clinical-trials-in-brazil-each-box-represents-a-key-step-in-the-process-and-the-arrows-show-the-order-in-which-these-steps-should-be-completed-follow-the-flow-to-understand-how-to-navigate-the-regulatory-landscape-effectively.webp", "https://images.tely.ai/telyai/lmoybooh-this-flowchart-shows-the-steps-you-need-to-take-to-get-approval-for-a-clinical-trial-in-brazil-start-at-the-top-and-follow-the-arrows-down-to-see-what-you-need-to-do-at-each-stage-including-what-documents-to-prepare-and-where-to-submit-them.webp", "https://images.tely.ai/telyai/ijcsaudr-each-box-represents-a-challenge-faced-during-the-approval-process-and-the-arrows-lead-to-strategies-that-can-help-overcome-these-challenges-follow-the-flow-to-see-how-to-tackle-each-obstacle-effectively.webp"], "inLanguage": "en", "author": {"@type": "Organization", "name": "bioaccess®"}, "publisher": {"@type": "Organization", "name": "bioaccess®", "url": "https://bioaccessla.com"}}</script>

  • Brazil’s 90‑Day ANVISA Clock for First‑in‑Human MedTech Studies: A Sponsor-Ready Timeline

    Brazil’s 90‑Day ANVISA Clock for First‑in‑Human MedTech Studies: A Sponsor-Ready Timeline

    For MedTech founders and regulatory leaders, the difference between a credible first‑in‑human (FIH) plan and an expensive science project often comes down to one question: when will we be cleared to start? In Latin America, Brazil is increasingly attractive because the regulatory environment is becoming more predictable for sponsors who prepare correctly. The biggest practical shift is that Brazil’s current framework is designed around a defined review window for ANVISA’s assessment of primary clinical‑trial petitions.

    This article translates that “clock” into a sponsor-ready activation timeline—what to do first, what can run in parallel, and where teams still lose weeks. It is written for early-stage device companies planning a first-in-human or very early feasibility study and aiming to use Brazil’s speed without compromising compliance.

    1) What the “ANVISA clock” changes (and what it does not)

    A defined review window is only valuable if your submission is complete and internally consistent. In practice, teams still face delays from avoidable dossier defects, mismatched translations, missing proof of manufacturer authorization, or unclear risk management documentation.

    • What changes: Sponsors can build a tighter critical path because the regulatory review is no longer an open-ended variable.
    • What does not change: Poor dossier quality, unclear clinical rationale, and weak local operational readiness can still extend the activation timeline.

    Think of the “90-day clock” as a predictability multiplier. It rewards teams that treat activation as a program, not a document handoff.

    2) A sponsor-ready activation timeline for FIH MedTech studies in Brazil

    Below is a practical timeline for a single-country Brazil activation that is common for early-stage MedTech programs. Actual sequencing depends on device risk classification, study design, and whether you already have an audited quality system and finalized manufacturing documentation.

    Phase A (Weeks 0–2): Define your regulatory “story” and activation plan

    Before drafting anything, align internal stakeholders on four elements:

    • Clinical intent: What data must your FIH generate (safety, usability, performance, feasibility) to unlock your next milestone?
    • Risk position: A simple, defensible summary of hazards, mitigations, and residual risk.
    • Operational model: Which hospitals, investigators, and vendor partners can execute within your required timeline?
    • Regulatory endpoints: Which approvals are required (ethics, ANVISA, contracts, importation readiness) and what is the critical path?

    Common failure mode: Teams finalize the protocol without deciding how the device will be imported, stored, serviced, and returned—creating late-stage amendments and logistics rework.

    Phase B (Weeks 2–6): Build the dossier as an integrated package

    FIH dossiers fail not because the science is wrong, but because the package is incoherent. Aim to produce a “single narrative” across these documents:

    • Protocol + investigator materials: Clear objectives, endpoints, and monitoring plan.
    • Device technical file excerpts: What the device is, how it works, and how it is controlled.
    • Risk management + usability: Evidence that use-related risks are addressed in training, labeling, and design controls.
    • Manufacturing and quality evidence: Enough to support safety and traceability expectations.
    • Clinical rationale: Why FIH is appropriate now and why Brazil’s sites can execute safely.

    Best practice: Maintain a “regulatory crosswalk” table mapping each claim in the protocol (device description, intended use, risk controls) to supporting evidence in the technical file. This prevents contradictions that trigger regulator questions.

    Phase C (Weeks 4–8): Ethics readiness and site operational lock

    While the dossier is being finalized, lock down the operational prerequisites that routinely delay activation:

    • Site feasibility confirmation: Not generic interest—confirmed equipment compatibility, OR slots, and patient flow.
    • Contracts and budget: Early alignment with hospital administration avoids last-minute legal stalls.
    • Training plan: How will you prove investigator training and competency for first uses?
    • Device logistics: Importation responsibilities, packaging validation, and field support processes.

    FIH timelines improve when ethics, contracts, and logistics are treated as first-class workstreams—not “post-approval tasks.”

    Phase D (Weeks 8–20): Regulatory review window and question management

    Once submitted, your main objective is to minimize cycles. Even with a defined review window, questions can reset practical timelines. Sponsors can reduce rework by planning for:

    • Rapid response capability: A named owner who can coordinate answers across engineering, QA/RA, and clinical.
    • Document control discipline: Consistent versioning, translation control, and traceability of edits.
    • Pre-drafted evidence packets: Sterilization summary, labeling package, risk management summary, device master record excerpts.

    Tip: When responding to questions, avoid “new storylines.” Keep answers anchored to the original intended use and risk position unless a formal amendment is required.

    3) Where FIH teams still lose time in Brazil

    Even with improved predictability, sponsors still lose weeks in three recurring areas:

    • Under-scoped translations: Technical and clinical translations require domain expertise, not generic language services.
    • Unclear importer/registration model: If responsibilities for importation and regulatory representation are not defined, device availability becomes the bottleneck.
    • Late site readiness: Contracts, budgets, and first-case scheduling often lag behind the regulatory path.

    The fix is not “work faster.” The fix is to design an activation system where regulatory, quality, and operations are integrated from day one.

    4) A practical checklist before you start your FIH activation

    • Have we defined the minimum FIH dataset required for our next financing or partnership step?
    • Is our intended use and risk position consistent across protocol, device description, and labeling?
    • Do we have a locked plan for importation, storage, servicing, and returns?
    • Are our sites contract-ready with budgets aligned and first-case logistics mapped?
    • Do we have a “rapid response” team prepared for regulator questions?

    FAQ: Brazil first‑in‑human MedTech study activation

    1) Can a defined review window guarantee my exact start date?

    No. It improves predictability, but start dates still depend on dossier quality, question cycles, ethics timing, contracts, and logistics.

    2) What is the most common avoidable delay for early-stage sponsors?

    Incoherent documentation—contradictions between protocol claims and device evidence, plus weak translation and version control.

    3) Should we activate Brazil as a stand-alone FIH or part of a multi-country plan?

    Many MedTech startups start with a focused single-country activation to generate clean early human data quickly, then expand once operational learning is captured.

    Conclusion: Brazil’s evolving framework can give FIH sponsors a more predictable regulatory path—but only if you build a dossier and activation plan that is operationally executable. Treat the “ANVISA clock” as a program milestone, not a date, and you can turn regulatory predictability into faster, safer first-in-human learning.

  • ANVISA confirms academic medical device studies in Brazil can skip regulatory review: what ANVISA Protocol 2025289179 and RDC 837/2023 mean for sponsors

    ANVISA confirms academic medical device studies in Brazil can skip regulatory review: what ANVISA Protocol 2025289179 and RDC 837/2023 mean for sponsors

    Originally published March 18, 2026. Rebuilt and updated June 20, 2026 with verbatim primary-source quotes from ANVISA Protocol 2025289179 and a dedicated section on the parallel importation authorization process.

    On December 9, 2025, ANVISA’s General Office of Technology Products for Health (GGTPS) issued a written clarification — Protocol No. 2025289179, signed by ANVISA officer Rafaela de Lima Avelino — confirming that strictly academic, non-commercialization clinical studies with medical devices can proceed in Brazil without prior ANVISA regulatory review. The clarification applies regardless of device risk class, meaning Class III and Class IV investigational devices qualify for this pathway if the study protocol explicitly excludes any intent to pursue Brazilian commercialization. Ethics Committee approval through CEP/CONEP remains required, but no ANVISA dossier is filed. For MedTech sponsors designing first-in-human (FIH) programs and evaluating where to run their earliest clinical evidence, this confirmation meaningfully changes the Brazil equation.

    What ANVISA’s December 9, 2025 protocol actually says

    ANVISA Protocol 2025289179 was issued in response to a direct query about the scope of regulatory oversight for academic, non-commercialization device studies under Brazilian law. The GGTPS (Gerência Geral de Tecnologia de Produtos para a Saúde) response confirmed the following position:

    Clinical investigations involving medical devices that are conducted exclusively for academic or scientific purposes — and that carry no present or prospective intent for commercialization in the Brazilian market — are not subject to prior ANVISA regulatory review under RDC 837/2023. Such studies require only Ethics Committee review and approval through the CEP/CONEP system, in line with the framework established under Lei 14.874/2024 and Decreto 12.651/2025.

    ANVISA’s verbatim language in the response (original Portuguese, with translation):

    “São passíveis de anuência emitida pela Anvisa apenas as investigações clínicas para dispositivos médicos cujo objetivo seja solicitar o registro do produto na Anvisa. Desta forma, em sendo o estudo realizado em ‘caráter estritamente acadêmico/científico e não possui finalidade de registro sanitário’ então é dispensável o atendimento a RDC supracitada.”

    Translation: “Only clinical investigations for medical devices whose objective is to request product registration with Anvisa are subject to consent issued by Anvisa. Therefore, if the study is carried out in a ‘strictly academic/scientific character and does not have the purpose of sanitary registration,’ then compliance with the aforementioned RDC is dispensable.”

    The protocol makes explicit that this exemption from pre-study ANVISA review applies across all device risk classes. A Class III or Class IV investigational device used in a study that meets the academic, non-commercialization criteria is treated the same as a lower-risk device for purposes of ANVISA pre-approval — the risk class does not trigger mandatory ANVISA review in this pathway.

    This is a significant regulatory clarification because the text of RDC 837/2023 itself, read in isolation, can create ambiguity about whether the exemption extends to higher-risk devices. Protocol 2025289179 resolves that ambiguity directly, in writing, from the responsible ANVISA directorate.

    Why this matters for Class III and IV device studies

    The prevailing assumption among many MedTech legal and regulatory teams has been that ANVISA review is categorically required before any clinical investigation of a Class III or IV device in Brazil, full stop. Protocol 2025289179 clarifies that this assumption is incorrect when the study is academic and non-commercialization in nature.

    The practical implications are substantial. A sponsor developing a novel implantable device, an active implantable device, a life-sustaining device, or any other product that falls into Brazil’s higher risk classifications can — provided the study protocol is correctly constructed — conduct a first-in-human study at a Brazilian academic medical center under CEP/CONEP review alone. No ANVISA Investigational Device Exemption equivalent dossier. No ANVISA review timeline. No ANVISA fee.

    For sponsors whose Brazilian clinical data will be used to support an FDA Investigational Device Exemption (IDE) or CE Mark application — and who have no immediate intent to pursue Brazilian ANVISA registration — this pathway keeps the regulatory burden proportionate to the study’s actual purpose.

    The distinction that triggers the exemption is not the device class. It is the study’s purpose. If the protocol is academic and the sponsor’s intent is non-commercialization in Brazil, the exemption applies.

    The four reinforcing primary sources

    The ANVISA clarification in Protocol 2025289179 does not stand alone. Four primary sources together form a coherent legal and regulatory basis for the CEP-only pathway in academic device studies.

    RDC 837/2023 — Brazilian Medical Device Clinical Investigation Regulation

    RDC 837/2023 is ANVISA’s operative regulation governing clinical investigations with medical devices. Article structures within the regulation define the scope of mandatory pre-study ANVISA review and carve out studies of a purely academic or scientific nature from that mandatory pathway. The regulation does not itself specify a risk-class threshold for the academic exemption, which is what created interpretive uncertainty — and which Protocol 2025289179 now resolves by confirming the exemption applies across all classes.

    Lei 14.874/2024 — Brazilian Clinical Research Law

    Lei 14.874/2024, enacted in 2024, is the overarching federal law governing clinical research in Brazil. Articles 2 XXI and 2 XXXII define key terms including “clinical investigation” and “strictly academic study,” drawing the boundary between studies that are and are not subject to full regulatory oversight. Article 58 addresses the CEP/CONEP approval pathway as the operative approval requirement for studies that fall outside mandatory ANVISA pre-review. The definitions in Lei 14.874/2024 are the legal anchor for the academic/non-commercialization distinction used in RDC 837/2023 and reinforced in Protocol 2025289179.

    Decreto 12.651/2025 — Operative Since October 8, 2025

    Decreto 12.651/2025, which entered into force on October 8, 2025, provides the executive regulatory framework implementing Lei 14.874/2024. Article 9 of the Decreto is particularly relevant: Item II describes the conditions under which a study requires full regulatory submission, while Item III describes the conditions — including the academic and non-commercialization criteria — under which a study may proceed under Ethics Committee review alone. The Decreto’s operative date (October 8, 2025) precedes the issuance of Protocol 2025289179 (December 9, 2025), confirming that the ANVISA clarification was issued in the context of a legal framework already in effect.

    ANVISA Protocol 2025289179 — GGTPS Written Response, December 9, 2025

    The written response from the General Office of Technology Products for Health (GGTPS — Gerência Geral de Tecnologia de Produtos para a Saúde), signed by ANVISA officer Rafaela de Lima Avelino, is the direct primary source confirming that the academic, non-commercialization exemption applies to all device risk classes. It is not a guidance document or a policy statement — it is a written regulatory position issued in response to a specific factual query. Its evidentiary weight for sponsors planning a CEP-only pathway is therefore high.

    Real-world precedent

    The academic/non-commercialization device study pathway in Brazil has not been purely theoretical in the period following the legislative and regulatory changes of 2024 and 2025. Recent Class III-equivalent device first-in-human studies have been conducted at leading academic medical centers in São Paulo under Ethics Committee approval, with no ANVISA dossier filed and no ANVISA enforcement action. These studies were sponsor-supported in their funding structure, with the protocols characterized as academic in purpose, and were designed to generate the clinical data required to support U.S. FDA IDE filings.

    bioaccess® does not disclose the identities of the sponsors, sites, or devices involved in its programs. What can be stated is that the pattern has emerged consistently: a MedTech sponsor with a novel device, a first-in-human objective, and no near-term Brazilian commercialization intent has been able to activate a study in Brazil without opening an ANVISA regulatory dossier, provided that the protocol was appropriately structured and that the importation authorization for the investigational device was obtained in parallel.

    Practitioners’ guides published in 2025 and 2026 acknowledge the academic study pathway as an established mechanism; specific commentary varies, and sponsors should rely primarily on the four primary sources cited above rather than on secondary guides. Sponsors who have engaged Brazilian regulatory counsel in advance of protocol finalization have generally navigated the CEP/CONEP process cleanly.

    Important caveats every sponsor should know

    Protocol 2025289179 is an important clarification, but it does not eliminate regulatory complexity. Sponsors considering the CEP-only pathway should understand four caveats before contracting.

    Caveat 1: The protocol must explicitly and unambiguously state no Brazilian registration intent.

    The academic/non-commercialization exemption is conditioned on the study’s purpose as documented. A protocol that is silent on Brazilian commercialization intent, or that includes ambiguous language such as references to potential future market development in Brazil, may not meet the threshold. Sponsors should work with Brazilian regulatory counsel to ensure the protocol language is explicit: the study is conducted for academic or scientific purposes, and the sponsor does not intend to use the data to support a Brazilian ANVISA registration application.

    Caveat 2: ANVISA importation clearance (RDC 172/2017) for the investigational device remains required.

    Obtaining CEP/CONEP approval without an ANVISA regulatory dossier does not exempt the sponsor from obtaining ANVISA importation clearance under RDC 172/2017 for the unregistered investigational device into Brazil. Importation authorization is a separate administrative process that runs in parallel with site activation. It is mechanically distinct from regulatory review of the study itself, and it must be completed before the device can physically enter Brazil for use in the study. Sponsors who plan for CEP/CONEP approval but fail to account for importation authorization timelines will encounter delays at the device logistics stage. bioaccess® manages this process as part of its standard activation workflow. See the dedicated importation section below for the full process.

    Caveat 3: CEP-only data cannot later be used for Brazilian registration. This is categorical, not a soft preference.

    This is the single most consequential limitation in Protocol 2025289179, and it is stated in unambiguous terms in ANVISA’s December 9, 2025 response. The verbatim Portuguese:

    “Entretanto, alertamos que os dados obtidos em investigações clínicas realizadas no Brasil com dispositivos médicos sem anuência prevista na RDC nº 837/2023, não poderão ser utilizados para comprovação de desempenho, eficácia e segurança junto à Anvisa para fins de registro em petições futuras.”

    Translation: “However, we warn that data obtained in clinical investigations carried out in Brazil with medical devices without the consent provided for in RDC No. 837/2023 cannot be used to prove performance, efficacy, and safety to Anvisa for registration purposes in future petitions.”

    A sponsor who later decides to commercialize the device in Brazil must run a separate, ANVISA-supervised registration study — the CEP-only EFS data is regulatorily inert for Brazilian registration purposes. This is not a position bioaccess® can negotiate or work around. It is the explicit text of ANVISA’s written confirmation, and it must be reflected in the sponsor’s regulatory strategy from day one. Sponsors who have any plausible path to Brazilian commercialization in their long-range plan should obtain a formal legal opinion on this point before choosing the CEP-only route.

    Caveat 4: Commercially-sponsored EFS studies warrant Brazilian legal opinion.

    The protocol-level distinction between an academic institution-led study and a commercially-sponsored Early Feasibility Study (EFS) involves nuances that are not fully resolved by RDC 837/2023 or Protocol 2025289179 alone. A commercially-structured EFS where the sponsor has meaningful involvement in study design, execution oversight, and data ownership introduces questions about whether the study meets the academic characterization under Lei 14.874/2024. This warrants a formal opinion from qualified Brazilian legal and regulatory counsel before the sponsor contracts for study execution.

    bioaccess® can refer sponsors to experienced Brazilian regulatory counsel and can coordinate the legal opinion process as part of trial planning. We do not substitute our operational expertise for legal advice, and we recommend that sponsors seeking certainty on these questions obtain a written legal opinion before committing to the CEP-only pathway.

    How the investigational device gets into Brazil — the importation layer ANVISA still controls

    ANVISA Protocol 2025289179 removes the requirement for pre-study ANVISA review of the clinical investigation itself. It does not remove ANVISA’s authority over what enters Brazil. Any foreign investigational medical device — regardless of whether the underlying study is registrational or non-registrational — requires ANVISA importation clearance before it can clear Brazilian customs. This is not a scientific review of the study; it is a separate administrative process handled by a different ANVISA unit, and it must be properly set up before the first device unit ships.

    Two distinct ANVISA functions, two distinct ANVISA units

    The clinical-trial review function (which Protocol 2025289179 deemed dispensable for academic, non-commercialization studies) sits with GGTPS — the Gerência Geral de Tecnologia de Produtos para a Saúde. The importation clearance function sits with PAFPS — Posto de Anuência de Importação de Produtos para Saúde, ANVISA’s Port, Airport, and Border post operating at points of entry. The two units operate under different regulations and different timelines. A sponsor running a CEP-only EFS is exempt from GGTPS clinical review but is not exempt from PAFPS importation clearance.

    ANVISA’s own clinical-research FAQ (CPPRO/GGTPS, November 13, 2024) is explicit on this point: for device clinical research outside DICD scope, “o processo de importação de dispositivos médicos … para fins de investigação clínica deve ser realizado como importação de bens e produtos destinados à pesquisa científica ou tecnológica e à pesquisa envolvendo seres humanos, de acordo com as Resoluções RDC nº 172/2017 e RDC nº 613/2022 e suas atualizações” — meaning the RDC 172/2017 research-importation pathway is the operative mechanism.

    Two importation pathways — and which one applies to non-registrational studies

    The applicable importation route is determined by the study’s purpose, and the two pathways are structurally distinct and non-overlapping.

    For studies that are intended to support Brazilian ANVISA registration (DICD-filed studies), the operative petition code is 90351 (“Anuência de Importação de produtos para saúde sob Pesquisa Clínica”), with regulatory basis in RDC 548/2021 and Chapters XXVI and XXVII of the Annex to RDC 81/2008. Under this pathway, the importer must hold an Autorização de Funcionamento (AFE) under RDC 16/2014, must submit a Termo de Responsabilidade per Chapter XXVII of the RDC 81/2008 Annex, and the import is anchored to an ANVISA-issued CE, CEE, or “Documento para Importação de Produto(s) sob Investigação” tied to the DICD authorization.

    For non-registrational EFS studies — the scenario addressed throughout this post — the applicable framework is RDC 172/2017 (as amended by RDC 613/2022), specifically Article 5, which governs importation of products under sanitary surveillance intended for “pesquisa envolvendo seres humanos sem fins de registro” (human research without registration purpose). RDC 172/2017 Article 1 item XIII defines this category in language that maps exactly to Lei 14.874/2024 Article 2 item XXXII. Article 7 of RDC 172/2017 confirms the structural separation: the research-importation provisions explicitly do not apply to registration-purpose studies, which use the DICD pathway. This produces a clean, binary, non-overlapping framework.

    Under the RDC 172/2017 pathway:
    – No AFE is required. Importers operating under RDC 172/2017 are explicitly exempt from the Autorização de Funcionamento requirement, per the 2024 ANVISA GCPAF workshop guidance and RDC 860/2024.
    – No CE, CEE, or “Documento para Importação” is issued. Those documents are DICD-linked and do not exist in the non-registration pathway.
    – The importation petition is filed via SISCOMEX with an LPCO (Licença, Permissão, Certificado ou Outro Documento) submission to PAFPS.
    – The specific 90xxx PAFPS petition code applicable to non-registrational device imports is not enumerated on ANVISA’s published April 2024 codes page — it is confirmed with the customs broker at filing time based on the device type and study context. Sponsors should engage a Brazilian customs broker with current PAFPS experience to confirm the operative code for the specific shipment. bioaccess® coordinates this through its Brazilian importation partner.

    Importer of record — who can legally bring the device into Brazil

    Under RDC 172/2017 Article 5 §4, importation by a natural person (pessoa física) of products subject to ANVISA regularization that have not yet been regularized is explicitly prohibited. The importer of record must be a Brazilian legal entity (pessoa jurídica). The foreign sponsor, unless it has a registered Brazilian subsidiary qualifying as a research importer, cannot act as importer directly.

    When the foreign sponsor is not the importer of record, the Brazilian importing entity acts under a delegation arrangement, and a Termo de Responsabilidade per Annex I of RDC 172/2017 must be signed by the Brazilian importer. RDC 613/2022 strengthened this Termo de Responsabilidade to include declaration of the inventory of all prior importations for the same research project, allowing PAFPS to verify quantities against the CEP-approved protocol.

    Article 6 of RDC 172/2017 establishes that importation by a legal entity for human research with unregularized products must be mandatorily preceded by CEP and, where applicable, CONEP approval of the study. This means the importation petition is filed after ethics committee clearance — not in advance of it. The Termo de Responsabilidade declares the CEP/CONEP approval status.

    Practical timeline — meaningfully faster than the registrational pathway

    The PAFPS authorization under RDC 172/2017 Article 5 §1 is required to be completed within 48 hours after the arrival of the goods in national territory, provided the SISCOMEX LI has been pre-registered and all required documentation is in order. For institutions credentialed by CNPq (the Brazilian National Council for Scientific and Technological Development) under a tax-exemption regime with the Federal Revenue Service, Article 5 §2 provides for automatic deferral of the SISCOMEX import license — meaning PAFPS clearance is granted without manual ANVISA review of the petition.

    This is materially faster than the DICD-linked registrational importation pathway, which involves ANVISA technical review and typically runs in the multi-week range. For a sponsor running a CEP-only EFS through a CNPq-credentialed institution or a Brazilian research importer with appropriate credentialing, the device can be on-site within days of arrival in Brazil, not weeks.

    Tax and customs treatment — meaningful benefits for credentialed importers

    Investigational devices entering Brazil under the RDC 172/2017 research-importation pathway qualify for a tax exemption stack that is not available under standard commercial importation:

    • Lei 8.010/1990 provides exemption from Imposto de Importação (II), Imposto sobre Produtos Industrializados (IPI), and Adicional ao Frete para Renovação da Marinha Mercante (AFRMM) for goods imported by CNPq-credentialed scientific and technological institutions or by entities importing through them.
    • Convênio ICMS 104/89 provides exemption from Imposto sobre Circulação de Mercadorias e Serviços (ICMS) at the state level, on the same terms.

    In practice, this means a CNPq-credentialed Brazilian research importer pays minimal tax and customs duty on the inbound investigational device shipment. For a foreign sponsor that has not yet established Brazilian research-importer credentialing, working with an importer of record that holds CNPq credentialing is the most direct route to capture these benefits. bioaccess® coordinates this credentialing pathway through its Brazilian importation partner.

    Documentation checklist for the RDC 172/2017 importation petition

    The core documentation required to support the PAFPS importation petition under RDC 172/2017 includes:

    • The CEP-approved (and, where applicable, CONEP-approved) study protocol, with the academic, non-commercialization purpose statement clearly documented
    • Termo de Responsabilidade signed by the Brazilian legal-entity importer of record, per Annex I of RDC 172/2017 (as updated by RDC 613/2022 to include inventory of prior importations)
    • Commercial invoice and bill of lading from the foreign supplier
    • Delegation document from the foreign sponsor authorizing the Brazilian importer, when the sponsor and importer are distinct legal entities
    • Secondary and external packaging labels for the investigational device showing the CEP-approved clinical protocol number, storage conditions (temperature, humidity, light exposure requirements), and lot or serial number sufficient for traceability throughout the study
    • SISCOMEX LI registration with the PAFPS-appropriate petition code, confirmed with the customs broker at filing time

    Packaging label compliance is frequently a cause of delay at the customs clearance stage. Labels must be prepared in Portuguese or in a bilingual format acceptable to ANVISA, and they must include all required fields before the shipment is tendered to the carrier.

    bioaccess® manages the full importation authorization workflow as part of its CRO scope, coordinating between the foreign sponsor, the Brazilian importer of record (with CNPq credentialing where appropriate to access the Lei 8.010/1990 and Convênio ICMS 104/89 tax exemptions), and PAFPS at the point of entry. For sponsors unfamiliar with the Brazilian research-importation framework, this is the component of study activation where the right local partner pays for itself in both timeline and total landed cost.

    What this means for first-in-human programs

    For MedTech sponsors evaluating where to run their first-in-human study, Protocol 2025289179 and the surrounding legal framework make Brazil more competitive than the regulatory overhead of the U.S. or EU pathway for academic device studies.

    A properly structured CEP-only study in Brazil activates through the ethics committee system. CEP/CONEP review timelines, while variable, have been compressing since the introduction of Lei 14.874/2024’s 90-business-day ANVISA review limit (which now creates a predictable ceiling on full-regulatory-pathway timelines as well). For academic studies, the absence of an ANVISA pre-submission requirement means the critical path is defined by CEP/CONEP, site contracting, and device importation — all of which bioaccess® manages as an integrated workflow.

    Brazil offers a combination of clinical infrastructure, patient population scale, experienced investigators at academic medical centers, and now a clarified regulatory pathway that reduces the administrative burden for academic device studies. For a MedTech startup running its first FIH study and targeting an FDA IDE or CE Mark — not a Brazilian commercial registration — the cost and timeline differential relative to conducting the same study in the U.S. or a Western European country is meaningful.

    bioaccess® was purpose-built for exactly this scenario: startups that need a high-quality, cost-efficient first-in-human study that generates FDA-credible data, with a CRO partner that understands both the operational and regulatory landscape in Latin America. We back our programs with a 12-month timeline guarantee because we have designed our workflows — including ANVISA importation authorization, CEP/CONEP management, and site activation — to run on a defined schedule.

    If you are evaluating Brazil for a device first-in-human study and want to understand whether the CEP-only pathway applies to your specific protocol and device class, the right next step is a direct conversation. Schedule a free consultation at bioaccessla.com/book-a-meeting.

    Frequently asked questions

    bioaccess® is a contract research organization (CRO) specializing in first-in-human clinical trials and market access for medical devices and biopharma in Latin America. This post is intended for general informational and educational purposes and does not constitute legal, regulatory, or medical advice. Sponsors should obtain qualified legal and regulatory counsel for their specific programs.

  • Best Practices for First in Human Trials in Brazil: Strategies for Success

    Best Practices for First in Human Trials in Brazil: Strategies for Success

    Introduction

    Brazil’s emergence as a key player in first-in-human trials presents both opportunities and challenges. Driven by a treatment-naive patient population and significant regulatory reforms, Brazil has rapidly positioned itself as a vital hub for clinical research.

    With the recent changes in Law No. 14,874/2024, the approval process has been streamlined, offering sponsors a remarkable opportunity to expedite their clinical research endeavors. However, navigating Brazil’s evolving regulatory landscape can be daunting for stakeholders.

    How can they effectively leverage Brazil’s unique advantages while overcoming the inherent challenges of patient recruitment and regulatory compliance? To succeed in early-stage clinical trials, stakeholders need to grasp these dynamics.

    Understand the Landscape of First-in-Human Trials in Brazil

    Brazil has emerged as a pivotal hub for first in human trial Brazil research, fueled by its diverse and treatment-naive patient population. The recent enactment of Law No. 14,874/2024 has reshaped the regulatory landscape significantly, reducing approval timelines from an average of 265 days to just 90 days. This reform simplifies the process. It also enhances the country’s appeal for first in human trial Brazil. Consequently, sponsors can expedite their research and development initiatives.

    The Brazilian regulatory body, ANVISA, plays a crucial role in supervising research studies, ensuring that they conform to international benchmarks such as ICH-GCP. This compliance is key to producing data that meets FDA and EMA standards, which is vital for attracting investment and facilitating market entry. Moreover, the incorporation of ethical review processes under the new regulations enhances efficiency and participant safety, bolstering the region’s status as a competitive force in the global research landscape.

    Grasping these dynamics is crucial for stakeholders aiming to leverage Latin America’s strategic benefits in early-stage research, particularly in the context of first in human trial Brazil. The integration of accelerated timelines, a strong regulatory system, and a diverse patient population establishes this nation as an ideal selection for early-stage clinical evaluations in the MedTech and Biopharma industries.

    This flowchart illustrates the key components of first-in-human trials in Brazil. Start at the top with the main topic, then follow the arrows to see how regulatory changes, the role of ANVISA, and benefits for stakeholders are interconnected. Each section highlights important aspects that contribute to Brazil's position in early-stage clinical research.

    Successfully conducting first-in-human (FIH) studies hinges on a thorough understanding of the regulatory framework in this region. The first step is to submit a Clinical Trial Application (CTA) to ANVISA. This application must include a comprehensive Drug Clinical Development Dossier (DDCM), which consists of the study protocol, informed consent forms, and investigator qualifications. ANVISA is required to provide a written opinion within 45 calendar days, followed by a final decision within a maximum of 90 working days. Following ICH-GCP guidelines helps ensure that the approval process goes smoothly. Additionally, obtaining approval from local ethics committees (CEPs) is mandatory, as their endorsement is a prerequisite for ANVISA’s review. Understanding these regulatory requirements and timelines allows sponsors to prepare their submissions efficiently. This reduces the risk of delays that could hinder study initiation. The nation’s efficient procedures and dedication to regulatory adherence establish it as a key site for first in human trial Brazil, offering notable benefits in speed and cost-effectiveness. Understanding these processes not only streamlines approvals but also positions the nation as a premier destination for clinical research.

    This flowchart outlines the steps needed to navigate regulatory requirements for clinical trials. Start with submitting your application, then follow the arrows to see what documents you need and the timelines for ANVISA's review and final decision. Don't forget to get approval from local ethics committees!

    Implement Efficient Strategies for Accelerated Trial Execution

    To accelerate trial execution in Latin America, sponsors must leverage the region’s unique advantages. Collaborating with established contract research organizations (CROs) is essential, as these partnerships provide invaluable insights into the local landscape. This collaboration enables quicker recruitment of participants and site selection. Local CROs excel at navigating Brazil’s regulatory environment, particularly with ANVISA, where approval timelines average 215 days – significantly longer than in many other regions. Working with these organizations allows sponsors to streamline submissions to ANVISA and CONEP. This ensures compliance with ICH-GCP standards and speeds up the approval process.

    Furthermore, using technology for data management and monitoring can really boost operational efficiency. It enables real-time adjustments and enhances data integrity. Implementing adaptive design approaches allows for flexibility in response to interim results, potentially reducing the overall duration of the study. Conducting comprehensive feasibility evaluations before study initiation can uncover potential obstacles and enhance the recruitment process. It’s important to note that 40% of clinical studies in Brazil fail due to low participant enrollment. This issue can be alleviated through improved education and awareness strategies, which local CROs can assist in implementing.

    By concentrating on these strategies, sponsors can significantly shorten timelines and lower costs, making their studies more competitive in the global landscape. The incorporation of local knowledge not only improves research efficiency but also establishes the region as a strategic center for early-stage studies. This leverages its diverse demographic and enhances access to treatment-naive groups. Utilizing insights from bioaccess’s Global Trial Accelerators™ can further enable MedTech and Biopharma innovators to effectively navigate the complexities of clinical studies in Latin America. By embracing these strategies, sponsors not only enhance their competitiveness but also position Latin America as a pivotal hub for clinical research.

    This flowchart outlines the key strategies for speeding up clinical trials in Latin America. Each box represents a strategy, and the arrows show how they connect to improve trial execution. Follow the flow to see how each step contributes to a more efficient process.

    Enhance Patient Recruitment and Engagement Strategies

    Recruiting and engaging participants effectively is a pivotal factor in the success of first in human trial Brazil. To build trust within local communities, sponsors should work closely with healthcare providers and advocacy groups. Engaging local stakeholders not only enhances credibility but also facilitates smoother recruitment processes. Digital platforms can greatly enhance visibility and accessibility. This is especially true for younger populations who engage more with online content.

    Tailoring recruitment messages to reflect cultural nuances and addressing potential barriers – such as language differences – can lead to higher enrollment rates. For instance, 24.1% of physicians observed a lack of research awareness among the population as a barrier to recruitment, emphasizing the necessity for targeted educational initiatives. Offering clear, accessible information about the research process and its potential advantages enables individuals to make informed choices regarding participation.

    Additionally, the Brazilian research environment offers distinct benefits, such as quicker enrollment of participants and reduced expenses compared to conventional markets. With regulatory organizations like ANVISA optimizing approval procedures, sponsors can anticipate faster timelines for commencing studies. In fact, the Brazilian medical research participant recruitment services market is projected to reach USD 144.4 million by 2033, reflecting a strong demand for recruitment services. By addressing obstacles such as prolonged approval durations – many sponsors struggle with lengthy approval processes, which can delay recruitment efforts – and the limited number of accessible studies, sponsors can improve patient involvement and ensure a consistent influx of participants throughout the research, ultimately aiding the success of their medical research initiatives.

    As one client pointed out, ‘Collaborating with bioaccess® enabled us to navigate the complexities of the Brazilian regulatory landscape efficiently, resulting in a successful launch ahead of schedule.’ This shows just how crucial it is to tap into local expertise and insights for better recruitment strategies. Bioaccess® is dedicated to leveraging these advantages, providing essential insights and strategies to accelerate clinical trials and market entry for MedTech and Biopharma companies in Latin America.

    The central idea is about enhancing recruitment strategies. Each branch represents a key area of focus, and the sub-branches provide specific actions or insights related to that area. This layout helps visualize how different strategies connect and contribute to the overall goal.

    Conclusion

    Brazil’s regulatory landscape presents both opportunities and challenges for first-in-human (FIH) trials, making it essential for sponsors to navigate it wisely. The recent regulatory reforms, particularly Law No. 14,874/2024, have significantly reduced approval timelines, making it an attractive option for sponsors looking to expedite their research and development processes. By capitalizing on Brazil’s unique advantages, stakeholders can enhance their clinical trial success rates while addressing the complexities of the local landscape.

    Let’s explore some best practices that can make FIH trials in Brazil successful. Key strategies include:

    • Collaborating with experienced contract research organizations (CROs) to facilitate smoother regulatory submissions and participant recruitment.
    • Prioritizing compliance with ANVISA and ICH-GCP guidelines to ensure studies meet international standards, which is vital for attracting investment.
    • Implementing targeted patient engagement strategies to significantly improve recruitment rates, addressing common barriers and enhancing overall trial efficiency.

    In conclusion, Brazil’s evolving regulatory environment and its commitment to fostering a conducive research atmosphere position it as a strategic hub for early-stage clinical trials. By adopting the outlined best practices, sponsors can not only capitalize on the country’s advantages of speed and cost-effectiveness but also contribute to the advancement of medical research in Latin America. By embracing these strategies, sponsors not only enhance their trial outcomes but also play a pivotal role in shaping the future of healthcare in Latin America.

    Frequently Asked Questions

    What recent changes have impacted first-in-human trials in Brazil?

    The enactment of Law No. 14,874/2024 has significantly reshaped the regulatory landscape for first-in-human trials in Brazil, reducing approval timelines from an average of 265 days to just 90 days.

    How does Brazil’s patient population benefit first-in-human trials?

    Brazil’s diverse and treatment-naive patient population provides a valuable resource for researchers conducting first-in-human trials, enhancing patient recruitment and the overall quality of clinical evaluations.

    What role does ANVISA play in first-in-human trials in Brazil?

    ANVISA, the Brazilian regulatory body, supervises research studies to ensure they conform to international standards such as ICH-GCP, which is essential for producing data that meets FDA and EMA standards.

    What are the compliance requirements for conducting first-in-human trials in Brazil?

    Compliance with international benchmarks like ICH-GCP is required, ensuring that research adheres to ethical standards and produces reliable data for market entry.

    How does the new regulation enhance participant safety in clinical trials?

    The incorporation of ethical review processes under the new regulations improves efficiency and participant safety, which is crucial for maintaining trust and integrity in clinical research.

    Why is Brazil considered a competitive force in the global research landscape?

    Brazil’s accelerated approval timelines, strong regulatory system, and diverse patient population establish it as an ideal location for early-stage clinical evaluations in the MedTech and Biopharma industries.

    What strategic advantages does Latin America offer for early-stage clinical trials?

    Latin America, particularly Brazil, offers speed in approval processes, cost efficiency, and effective patient recruitment, making it a strategic advantage for conducting early-stage clinical trials.

    List of Sources

    1. Understand the Landscape of First-in-Human Trials in Brazil
      • statista.com (https://statista.com/statistics/1067453/brazil-number-clinical-trials-initiated?srsltid=AfmBOorNeHMRYCS3WQDds59a6Iv28RyooIach1XHknXX6qQftk0GdNwp)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil)
      • lickslegal.com (https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil)
      • lexology.com (https://lexology.com/library/detail.aspx?g=b1b655f4-963a-4be7-876c-81afb05caef6)
    2. Navigate Regulatory Requirements for Clinical Trials
      • linkedin.com (https://linkedin.com/posts/cristiane-salles-36bbb336_clinicalresearch-brazil-clinicaltrials-activity-7434614266575560704-Kn4L)
      • lickslegal.com (https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil)
      • credevo.com (https://credevo.com/articles/2019/03/14/clinical-trial-regulatory-process-brazil)
      • linkedin.com (https://linkedin.com/posts/bioaccess_clinicaltrials-brazil-anvisa-activity-7447976698958106627-98MW)
      • bioaccessla.com (https://bioaccessla.com/blog/brazil-anvisa-parallel-review-clinical-trial-approvals-2026)
    3. Implement Efficient Strategies for Accelerated Trial Execution
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10898894)
      • lek.com (https://lek.com/insights/life-sciences-pharma/unlocking-brazils-clinical-trial-opportunity-strategic-roadmap)
      • pharmaphorum.com (https://pharmaphorum.com/views-and-analysis/accelerating-clinical-research-brazil)
    4. Enhance Patient Recruitment and Engagement Strategies
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trial-patient-recruitment-services-market/brazil)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10898894)
      • statista.com (https://statista.com/statistics/1067453/brazil-number-clinical-trials-initiated?srsltid=AfmBOopZcK_QgUFOSPSk-AkVnIixO9riFznsGp0hqgHHsDLIMGY9VpCC)